0001962011 2025-01-01 2025-12-31 0001962011 2025-06-30 0001962011 2026-03-31 0001962011 2024-01-01 2024-12-31 0001962011 2025-12-31 0001962011 2024-12-31 0001962011 us-gaap:CommonStockMember 2023-12-31 0001962011 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001962011 us-gaap:RetainedEarningsMember 2023-12-31 0001962011 2023-12-31 0001962011 us-gaap:CommonStockMember 2024-12-31 0001962011 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001962011 us-gaap:RetainedEarningsMember 2024-12-31 0001962011 us-gaap:CommonStockMember 2024-01-01 2024-12-31 0001962011 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-12-31 0001962011 us-gaap:RetainedEarningsMember 2024-01-01 2024-12-31 0001962011 us-gaap:CommonStockMember 2025-01-01 2025-12-31 0001962011 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-12-31 0001962011 us-gaap:RetainedEarningsMember 2025-01-01 2025-12-31 0001962011 us-gaap:CommonStockMember 2025-12-31 0001962011 us-gaap:AdditionalPaidInCapitalMember 2025-12-31 0001962011 us-gaap:RetainedEarningsMember 2025-12-31 0001962011 KAPA:EnviroThreapeuticsIncMember 2021-12-31 0001962011 KAPA:EquityLineOfCreditMember 2024-12-31 0001962011 KAPA:EquityLineOfCreditMember 2025-12-31 0001962011 us-gaap:PatentsMember 2025-01-01 2025-12-31 0001962011 us-gaap:PatentsMember 2024-01-01 2024-12-31 0001962011 KAPA:WarrantsToPurchaseCommonStockMember 2025-01-01 2025-12-31 0001962011 KAPA:WarrantsToPurchaseCommonStockMember 2024-01-01 2024-12-31 0001962011 us-gaap:RestrictedStockUnitsRSUMember 2025-01-01 2025-12-31 0001962011 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-12-31 0001962011 KAPA:PrevailInfoworksIncMember 2025-12-31 0001962011 KAPA:PrevailInfoworksIncMember 2024-12-31 0001962011 KAPA:PreCheckHealthServicesIncMember 2025-12-31 0001962011 KAPA:PreCheckHealthServicesIncMember 2024-12-31 0001962011 KAPA:CEOCATechnologiesLtdMember 2025-12-31 0001962011 KAPA:CEOCATechnologiesLtdMember 2024-12-31 0001962011 KAPA:BelairCapitalAdvisorsIncMember 2025-12-31 0001962011 KAPA:BelairCapitalAdvisorsIncMember 2024-12-31 0001962011 KAPA:CrossCurrentCapitalLLCMember 2025-12-31 0001962011 KAPA:CrossCurrentCapitalLLCMember 2024-12-31 0001962011 KAPA:MasterServiceAndTechnologyAgreementMember 2024-08-01 2024-08-01 0001962011 KAPA:MasterServiceAndTechnologyAgreementMember 2025-12-31 0001962011 KAPA:BioassayServicesAgreementMember KAPA:PreCheckHealthServicesIncMember 2024-09-20 2024-09-20 0001962011 KAPA:BioassayServicesAgreementMember KAPA:PreCheckHealthServicesIncMember 2025-01-01 2025-12-31 0001962011 KAPA:BioassayServicesAgreementMember KAPA:PreCheckHealthServicesIncMember 2024-01-01 2024-12-31 0001962011 KAPA:AdvisoryAndConsultingServicesAgreementMember KAPA:CEOCATechnologiesLtdMember 2024-09-23 2024-09-23 0001962011 KAPA:AdvisoryAndConsultingServicesAgreementMember KAPA:CEOCATechnologiesLtdMember 2025-01-01 2025-12-31 0001962011 KAPA:AdvisoryAndConsultingServicesAgreementMember KAPA:CEOCATechnologiesLtdMember 2024-01-01 2024-12-31 0001962011 KAPA:StrategicAdvisoryAgreementMember KAPA:BelairCapitalAdvisorsIncMember 2024-09-23 2024-09-23 0001962011 KAPA:StrategicAdvisoryAgreementMember KAPA:BelairCapitalAdvisorsIncMember 2025-01-01 2025-12-31 0001962011 KAPA:StrategicAdvisoryAgreementMember KAPA:BelairCapitalAdvisorsIncMember 2024-01-01 2024-12-31 0001962011 KAPA:ConsultingAgreementMember 2024-10-01 2024-10-01 0001962011 KAPA:ConsultingAgreementMember 2025-12-31 0001962011 KAPA:ConsultingAgreementMember 2024-12-31 0001962011 KAPA:ConsultingAgreementMember 2025-04-01 2025-04-01 0001962011 us-gaap:CommonStockMember KAPA:ConsultingAgreementMember 2025-04-01 2025-04-01 0001962011 KAPA:HelenaGlobalInvestmentOpportunitiesILTDMember 2024-11-12 2024-11-12 0001962011 2024-11-12 2024-11-12 0001962011 us-gaap:CommonStockMember KAPA:HelenaGlobalInvestmentOpportunitiesILTDMember 2025-04-24 2025-04-24 0001962011 KAPA:HelenaGlobalInvestmentOpportunitiesILTDMember 2025-01-01 2025-12-31 0001962011 2023-05-10 0001962011 us-gaap:IPOMember 2024-09-17 2024-09-17 0001962011 us-gaap:IPOMember 2024-09-17 0001962011 us-gaap:IPOMember 2024-09-16 2024-09-16 0001962011 us-gaap:IPOMember 2025-01-01 2025-12-31 0001962011 us-gaap:IPOMember KAPA:UnderwrintingAgreementMember 2024-09-17 2024-09-17 0001962011 us-gaap:IPOMember KAPA:UnderwrintingAgreementMember 2024-09-17 0001962011 us-gaap:ConvertibleNotesPayableMember 2022-12-31 0001962011 us-gaap:ConvertibleNotesPayableMember 2024-09-17 0001962011 us-gaap:ConvertibleNotesPayableMember 2025-01-01 2025-12-31 0001962011 us-gaap:ConvertibleNotesPayableMember us-gaap:CommonStockMember 2024-09-17 2024-09-17 0001962011 KAPA:CedarsSinaiMedicalCenterMember 2024-01-01 2024-12-31 0001962011 KAPA:CedarsSinaiMedicalCenterMember 2024-12-31 0001962011 KAPA:AnotherCedarsSinaiMedicalCenterMember 2024-01-01 2024-12-31 0001962011 KAPA:AnotherCedarsSinaiMedicalCenterMember 2024-12-31 0001962011 srt:ChiefFinancialOfficerMember 2024-01-01 2024-12-31 0001962011 srt:ChiefFinancialOfficerMember 2024-12-31 0001962011 us-gaap:RelatedPartyMember 2021-12-31 0001962011 us-gaap:RelatedPartyMember 2024-09-17 0001962011 us-gaap:CommonStockMember KAPA:SixtyPercentageOfIPOClosingPriceMember 2024-12-31 0001962011 srt:OfficerMember 2024-01-01 2024-12-31 0001962011 us-gaap:RestrictedStockUnitsRSUMember KAPA:CrossCurrentCapitalLLCMember 2024-10-01 2024-10-01 0001962011 KAPA:PreFundedWarrantMember KAPA:SecurityPurchaseAgreementMember 2025-01-14 2025-01-14 0001962011 KAPA:PreFundedWarrantMember KAPA:SecurityPurchaseAgreementMember 2025-01-14 0001962011 us-gaap:WarrantMember KAPA:SecurityPurchaseAgreementMember 2025-01-14 0001962011 KAPA:SecurityPurchaseAgreementMember 2025-01-16 2025-01-16 0001962011 KAPA:SecurityPurchaseAgreementMember 2025-01-16 0001962011 KAPA:PrefundedWarrantsMember 2025-01-14 0001962011 KAPA:CommonWarrantsMember 2025-01-14 0001962011 2025-01-14 2025-01-14 0001962011 KAPA:PrefundedWarrantsMember 2025-01-01 2025-12-31 0001962011 KAPA:TwentyTwentyThreeEquityIncentivePlanMember 2023-07-31 0001962011 KAPA:TwentyTwentyThreeEquityIncentivePlanMember 2025-12-31 0001962011 KAPA:TwentyTwentyThreeEquityIncentivePlanMember 2024-12-31 0001962011 srt:BoardOfDirectorsChairmanMember us-gaap:RestrictedStockUnitsRSUMember 2025-10-08 2025-10-08 0001962011 us-gaap:RestrictedStockUnitsRSUMember KAPA:TwoThousandTwentyThreeEquityIncentivePlanMember 2025-10-08 2025-10-08 0001962011 us-gaap:RestrictedStockUnitsRSUMember KAPA:StrategicAdvisoryAgreementMember 2024-09-23 2024-09-23 0001962011 us-gaap:RestrictedStockUnitsRSUMember KAPA:StrategicAdvisoryAgreementMember 2024-01-01 2024-12-31 0001962011 us-gaap:RestrictedStockUnitsRSUMember KAPA:StrategicAdvisoryAgreementMember 2025-01-01 2025-12-31 0001962011 us-gaap:RestrictedStockUnitsRSUMember KAPA:FourOfficersAgreementMember 2024-09-01 2024-09-30 0001962011 us-gaap:RestrictedStockUnitsRSUMember KAPA:FourOfficersAgreementMember 2024-01-01 2024-12-31 0001962011 us-gaap:RestrictedStockUnitsRSUMember KAPA:FourOfficersAgreementMember 2025-01-01 2025-12-31 0001962011 srt:DirectorMember us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-12-31 0001962011 srt:DirectorMember us-gaap:RestrictedStockUnitsRSUMember 2025-01-01 2025-12-31 0001962011 us-gaap:RestrictedStockUnitsRSUMember 2025-01-01 2025-12-31 0001962011 us-gaap:RestrictedStockUnitsRSUMember 2025-12-31 0001962011 us-gaap:InvestorMember KAPA:PreFundedWarrantMember KAPA:SecurityPurchaseAgreementMember 2025-01-16 0001962011 us-gaap:InvestorMember KAPA:PreFundedWarrantMember KAPA:SecurityPurchaseAgreementMember 2025-12-31 0001962011 us-gaap:InvestorMember us-gaap:WarrantMember KAPA:SecurityPurchaseAgreementMember 2025-12-31 0001962011 us-gaap:InvestorMember us-gaap:WarrantMember KAPA:SecurityPurchaseAgreementMember 2025-01-01 2025-12-31 0001962011 us-gaap:CommonStockMember 2025-01-16 0001962011 us-gaap:WarrantMember 2025-01-16 0001962011 KAPA:UnderwritersMember us-gaap:WarrantMember KAPA:SecurityPurchaseAgreementMember 2025-01-16 2025-01-16 0001962011 us-gaap:CommonStockMember 2025-05-31 0001962011 us-gaap:CommonStockMember 2025-06-30 0001962011 us-gaap:WarrantMember 2025-05-31 0001962011 us-gaap:WarrantMember 2025-06-30 0001962011 KAPA:UnderwritersMember us-gaap:WarrantMember KAPA:SecurityPurchaseAgreementMember 2025-05-01 2025-05-31 0001962011 KAPA:UnderwritersMember us-gaap:WarrantMember KAPA:SecurityPurchaseAgreementMember 2025-06-01 2025-06-30 0001962011 us-gaap:WarrantMember KAPA:SecurityPurchaseAgreementMember 2025-01-01 2025-12-31 0001962011 us-gaap:WarrantMember KAPA:SecurityPurchaseAgreementMember 2025-12-31 0001962011 us-gaap:CommonStockMember 2025-07-31 0001962011 us-gaap:WarrantMember 2025-07-31 0001962011 KAPA:UnderwritersMember us-gaap:WarrantMember KAPA:SecurityPurchaseAgreementMember 2025-07-01 2025-07-31 0001962011 us-gaap:WarrantMember 2024-09-17 0001962011 KAPA:WarrantOneMember 2024-09-17 0001962011 KAPA:WarrantOneMember 2024-09-17 2024-09-17 0001962011 KAPA:WarrantOneMember 2024-10-01 2024-12-31 0001962011 us-gaap:WarrantMember 2025-12-31 0001962011 us-gaap:RestrictedStockUnitsRSUMember 2023-12-31 0001962011 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-12-31 0001962011 us-gaap:RestrictedStockUnitsRSUMember 2024-12-31 0001962011 us-gaap:WarrantMember 2023-12-31 0001962011 us-gaap:WarrantMember 2024-01-01 2024-12-31 0001962011 srt:MinimumMember us-gaap:WarrantMember 2024-01-01 2024-12-31 0001962011 srt:MaximumMember us-gaap:WarrantMember 2024-01-01 2024-12-31 0001962011 us-gaap:WarrantMember 2024-12-31 0001962011 srt:MinimumMember us-gaap:WarrantMember 2024-12-31 0001962011 srt:MaximumMember us-gaap:WarrantMember 2024-12-31 0001962011 us-gaap:WarrantMember 2025-01-01 2025-12-31 0001962011 srt:MinimumMember us-gaap:WarrantMember 2025-01-01 2025-12-31 0001962011 srt:MaximumMember us-gaap:WarrantMember 2025-01-01 2025-12-31 0001962011 srt:MinimumMember us-gaap:WarrantMember 2025-12-31 0001962011 srt:MaximumMember us-gaap:WarrantMember 2025-12-31 0001962011 srt:MinimumMember KAPA:ExercisePriceRangeOneMember KAPA:WarrantOneMember 2025-12-31 0001962011 srt:MaximumMember KAPA:ExercisePriceRangeOneMember KAPA:WarrantOneMember 2025-12-31 0001962011 KAPA:ExercisePriceRangeOneMember KAPA:WarrantOneMember 2025-12-31 0001962011 KAPA:ExercisePriceRangeOneMember KAPA:WarrantOneMember 2025-01-01 2025-12-31 0001962011 srt:MinimumMember KAPA:ExercisePriceRangeTwoMember KAPA:WarrantTwoMember 2025-12-31 0001962011 srt:MaximumMember KAPA:ExercisePriceRangeTwoMember KAPA:WarrantTwoMember 2025-12-31 0001962011 KAPA:ExercisePriceRangeTwoMember KAPA:WarrantTwoMember 2025-12-31 0001962011 KAPA:ExercisePriceRangeTwoMember KAPA:WarrantTwoMember 2025-01-01 2025-12-31 0001962011 KAPA:ExercisePriceRangeThreeMember KAPA:WarrantThreeMember 2025-12-31 0001962011 KAPA:ExercisePriceRangeThreeMember KAPA:WarrantThreeMember 2025-01-01 2025-12-31 0001962011 KAPA:ExclusiveLicenseAgreementMember 2025-01-01 2025-12-31 0001962011 srt:MinimumMember KAPA:ExclusiveLicenseAgreementMember 2025-01-01 2025-12-31 0001962011 srt:MaximumMember KAPA:ExclusiveLicenseAgreementMember 2025-01-01 2025-12-31 0001962011 KAPA:PhaseOneClinicalTrialMember 2025-01-01 2025-12-31 0001962011 KAPA:ItemOneAndTwoMember KAPA:PhaseTwoMember 2025-01-01 2025-12-31 0001962011 KAPA:ItemThreeMember KAPA:PhaseTwoClinicalTrialMember 2025-01-01 2025-12-31 0001962011 us-gaap:NonUsMember KAPA:FoodAndDrugAdministrationMember 2025-01-01 2025-12-31 0001962011 KAPA:ItemOneTwoAndThreeMember 2025-01-01 2025-12-31 0001962011 KAPA:ItemFourMember KAPA:ExclusiveLicenseAgreementMember 2025-01-01 2025-12-31 0001962011 KAPA:ItemFourMember KAPA:ExclusiveLicenseAgreementMember 2025-12-31 0001962011 KAPA:ItemFourMember srt:MinimumMember KAPA:ExclusiveLicenseAgreementMember 2025-01-01 2025-12-31 0001962011 KAPA:ItemFourMember srt:MaximumMember KAPA:ExclusiveLicenseAgreementMember 2025-01-01 2025-12-31 0001962011 KAPA:ItemFourMember KAPA:PhaseOneClinicalTrialMember 2025-01-01 2025-12-31 0001962011 KAPA:ItemFourMember KAPA:PhaseTwoClinicalTrialMember 2025-01-01 2025-12-31 0001962011 KAPA:ItemFourMember KAPA:FoodAndDrugAdministrationMember 2025-01-01 2025-12-31 0001962011 KAPA:ItemFourMember 2025-01-01 2025-12-31 0001962011 KAPA:PhaseThreeClinicalTrialMember KAPA:EnviroCedarsLicenseAgreementsMember 2025-01-01 2025-12-31 0001962011 KAPA:ItemOneAndTwoMember KAPA:PhaseThreeMember KAPA:EnviroCedarsLicenseAgreementsMember 2025-01-01 2025-12-31 0001962011 KAPA:LonzaAmendmentMember 2025-11-12 2025-11-12 0001962011 KAPA:SettlementAgreementMember 2024-10-17 2024-10-17 0001962011 KAPA:SettlementAgreementMember 2024-10-01 2024-10-31 0001962011 KAPA:SettlementAgreementMember 2024-12-31 0001962011 us-gaap:OperatingSegmentsMember 2025-01-01 2025-12-31 0001962011 us-gaap:OperatingSegmentsMember 2024-01-01 2024-12-31 0001962011 us-gaap:SubsequentEventMember 2026-01-01 2026-01-31 0001962011 us-gaap:SubsequentEventMember KAPA:ATMAgreementMember 2026-01-01 2026-01-31 0001962011 us-gaap:SubsequentEventMember KAPA:ATMAgreementMember 2026-01-01 2026-03-31 0001962011 us-gaap:SubsequentEventMember 2026-03-02 0001962011 us-gaap:SubsequentEventMember 2026-03-02 2026-03-02 0001962011 us-gaap:SubsequentEventMember KAPA:LonzaAmendmentMember 2026-03-27 2026-03-27 iso4217:USD shares iso4217:USD shares pure KAPA:Integer false FY 0001962011

10-K true 2025-12-31 --12-31 2025 false 001-42275 KAIROS PHARMA, LTD. DE 46-2993314 2355 Westwood Blvd. #139 Los Angeles CA 90064 (310) 948-2356 Common Stock, par value $0.001 per share KAPA NYSEAMER No No Yes Yes Non-accelerated Filer true true false false false false 6900000 21411198 Risk Management and Strategy<span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_900_ecyd--CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_dbT_c20250101__20251231_zUphp77Tfvml">We routinely assess material risks from cybersecurity threats, including any potential unauthorized occurrence on or conducted through our information systems that may result in adverse effects on the confidentiality, <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_903_ecyd--CybersecurityRiskManagementProcessesIntegratedFlag_dbT_c20250101__20251231_zAdtsh6kxV09">integrity, or availability of our information systems or any information residing therein. We conduct risk assessments at least annually to identify cybersecurity threats. These risk assessments include identifying reasonably foreseeable potential internal and external risks, the likelihood of occurrence and any potential damage that could result from such risks, and the sufficiency of existing policies, procedures, systems, controls and other safeguards we have put in place to manage such risks. Our risk management process also encompasses cybersecurity risks associated with the use of our major <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_906_ecyd--CybersecurityRiskManagementThirdPartyEngagedFlag_dbT_c20250101__20251231_zanR3gl2Z7Ee">third-party vendors and service providers. For additional information regarding whether any risks from cybersecurity threats, including as a result of any previous cybersecurity incidents, have materially affected or are reasonably likely to materially affect our company, including our business strategy, results of operations, or financial condition, please refer to Item 1A “Risk Factors” in this Annual Report on Form 10-K , including the risk factors entitled “Our internal computer systems, or those of our CROs or other contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of our product development programs,” and “Our proprietary information, or that of our customers, suppliers and business partners, may be lost or we may suffer security breaches.” true true true One of the key functions of our <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90B_ecyd--CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_c20250101__20251231_zuSWvsnwOOE3">Board of Directors is informed oversight of our risk management process, including risks arising from cybersecurity threats. <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_902_ecyd--CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_c20250101__20251231_zTXeW2ZGzrL7">Our Board of Directors is responsible for monitoring and assessing strategic risk exposure, and our executive officers are responsible for the day-to-day management of the material risks we face. Our Chief Financial Officer is primarily responsible for assessing and managing material risks from cybersecurity threats on a day to day basis. Board of Directors is informed oversight of our risk management process, including risks arising from cybersecurity threats. Our Board of Directors is responsible for monitoring and assessing strategic risk exposure, and our executive officers are responsible for the day-to-day management of the material risks we face. Our Chief Financial Officer is primarily responsible for assessing and managing material risks from cybersecurity threats on a day to day basis. 572 688 We have audited the accompanying consolidated balance sheet of Kairos Pharma, Ltd. (the “Company”) as of December 31, 2025, the related consolidated statements of operations, changes in shareholders’ equity (deficit) and cash flows for the year ended December 31, 2025, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2025, and the results of its operations and its cash flows for the year ended December 31, 2025, in conformity with accounting principles generally accepted in the United States of America. Weinberg & Company P.A. Los Angeles, CA Marcum LLP Los Angeles, CA

4491000

1272000

845000 2859000

51000

38000

5387000

4169000

1091000

1377000

62000

222000

1153000

1599000

6540000

5768000

199000

992000

199000

992000

0.001

20000000

0.001

100000000

20821353

13736597

21000

14000

20582000

13577000

-14262000

-8815000

6341000

4776000

6540000

5768000

2135000

414000

3437000

1929000

5572000

2343000

-5572000

-2343000

35000

154000

670000

599000

125000

-260000

-5447000

-2603000

-0.30

-0.23

18427787

11356451

10562640

11000

4123000

-6212000

-2078000

1550000

2000

4650000

4652000

368371

884000

514940

1789000

1664

7000

670641

1000

1877000

1878000

29000

68341

218000

-2603000

13736597

14000

13577000

-8815000

4776000

2500000 2000 3056000 3058000 384459 327000 327000 3510000 4000 2984000 2988000 534188 1000 156000 157000

144707

482000

11402

-5447000

20821353

21000

20582000

-14262000

6341000

-5447000

-2603000

160000

2170000

154000

482000 218000 670000 29000 599000 2358000

13000

30000

-793000

404000

-3441000

-3955000

3058000

3602000

5524000

142000

390000

6660000

5134000

3219000

1179000

1272000

93000

4491000

1272000

3000

327000 1377000 157000 500000 614000 872000 884000 1348000 4000 49000

NOTE 1 – BASIS OF PRESENTATION Organization and Operations Kairos Pharma, Ltd. (the “Company” or “Kairos”) was incorporated on June 17, 2013 under the laws of the state of California as NanoGB13, Inc. The Company changed its name to Kairos Pharma, Ltd. on July 15, 2016 and subsequently converted into a Delaware corporation under the same name, Kairos Pharma, Ltd., on May 10, 2023. The Company is an early-stage biotechnology company focused on the development of immunotherapy and cell therapy treatments for oncology. Liquidity and Capital Resources The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. As reflected in the accompanying consolidated financial statements, the Company has experienced recurring losses from operations since inception and incurred a net loss of $5,447 and used cash in operations of $3,441 during the year ended December 31, 2025. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The ability of the Company to continue as a going concern is dependent upon the Company’s ability to raise additional funds and implement its strategies. The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. As of December 31, 2025, the Company had cash and short-term investments of $4,491. Until we can generate sufficient product revenue to finance our cash requirements, which we may never do, we expect to finance our future cash needs through a combination of public or private equity offerings and debt financings, or other capital sources such as potential collaborations, strategic alliances, licensing arrangements and other arrangements. Based on our research and development plans, we expect that our existing cash balance may not enable us to fund our planned operating expenses and capital expenditure requirements for at least the next 12 months from the date of filing of this Annual Report. We have based this estimate on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect. In addition, because the design and outcome of our anticipated and any future clinical trials is highly uncertain, we cannot reasonably estimate the actual amounts necessary to successfully complete the development and commercialization of our current products or any future product candidates. Additionally, although we have the ability to raise funds through our Form S-1 and S-3 registration statements filed in 2025 and 2026, we may not receive some or all of these available proceeds, due to certain factors. The failure to receive all or some of the proceeds would exhaust our available capital resources sooner than expected and will require us to obtain further funding to achieve our business objectives. No assurance can be given that any future financing will be available or, if available, that it will be on terms that are satisfactory to the Company. Even if the Company is able to obtain additional financing, it may contain undue restrictions on our operations, in the case of debt financing, or cause substantial dilution for our shareholders, in the event of an equity financing.

-5447000

-3441000

4491000

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Consolidation The accompanying consolidated financial statements and accompanying notes have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). The accompanying consolidated financial statements include the accounts of the Company and its former wholly-owned subsidiary, Enviro Therapeutics, Inc. (“Enviro”) which was dissolved in October 2025. All intercompany balances and transactions have been eliminated in consolidation. Use of Estimates The preparation of the financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the financial statement date and reported amounts of revenue and expenses during the reporting period. Significant estimates are used in the valuation of accruals for potential liabilities, amortization of vendor advances and deferred offering costs, valuations of stock-based compensation, the realization of deferred tax assets, and impairment analysis and useful life for intangible assets among others. Actual results could differ from these estimates. Concentration of Credit Risk Financial instruments, which potentially subject the Company to concentration of credit risk, consist primarily of cash deposits. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. Management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. The Company has not experienced any losses on deposits since its inception. Cash Equivalents The Company considers all highly liquid investments with original maturities of three months or less on the date of purchase to be cash equivalents. The Company’s cash equivalents consisted of $4,326 in money market funds as of December 31, 2025. There were no cash equivalents as of December 31, 2024. The underlying securities in the money market funds held by the Company are all government backed securities. Intangible Assets The Company’s intangible assets are stated at fair value as of the date acquired, less accumulated amortization. Amortization is calculated based on the estimated useful lives of the assets, which were determined to be five years, using the straight-line method. The intangible asset consists of a licensing agreement that the Company acquired through its acquisition of Enviro during the year ended December 31, 2021, with an acquisition cost of $<span id="xdx_90F_eus-gaap--BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_iI_pn3n3_c20211231__us-gaap--BusinessAcquisitionAxis__custom--EnviroThreapeuticsIncMember_z03lWFWQPhf7" title="Acquisition cost">800. Amortization expense relating to the intangible asset during the years ended December 31, 2025 and 2024 was $160, with an unamortized balance of $62 and $222 at December 31, 2025 and 2024, respectively. Impairment of Long-Lived Assets The Company applies the provisions of ASC Topic 360, Property, Plant, and Equipment, which addresses financial accounting and reporting for the impairment of long-lived assets. A long-lived asset that is held and used should be tested for recoverability whenever events or changes in circumstances indicate that the carrying amount of the asset group may not be recoverable. If the estimated undiscounted future cash flows are less than the carrying value, an impairment determination is required. In that event, a loss is recognized based on the amount by which the carrying amount exceeds the fair value of the long-lived assets. No impairment was recorded relating to the Company’s intangible asset during the years ended December 31, 2025 and 2024. Income (Loss) Per Share Basic loss per share is computed by dividing net loss applicable to common stockholders by the weighted average number of outstanding common shares during the period. Shares of restricted stock are included in the basic weighted average number of common shares outstanding from the time they vest. Diluted loss per share is computed by dividing the net loss applicable to common stockholders by the weighted average number of common shares outstanding plus the number of additional common shares that would have been outstanding if all dilutive potential common shares had been issued. <p id="xdx_895_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zWBC5khKxgC1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">For the years ended December 31, 2025 and 2024, the basic and diluted shares outstanding were the same, as potentially dilutive shares were considered anti-dilutive. The potentially dilutive securities consisted of the following: SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49A_20250101__20251231_ztrOqxIRJUo" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20240101__20241231_zWrdaWbwoZt2" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_405_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsToPurchaseCommonStockMember_zSdwG3fjWBld" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: justify">Warrants to purchase common stock</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 18%; text-align: right">4,281,038</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 18%; text-align: right">278,188</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_z6cLrSkqe64d" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">Restricted stock units</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">772,605</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">172,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zM0KPOzyAVxa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">5,053,643</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">450,188</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Deferred Offering Costs The Company capitalizes certain legal, professional, accounting and other third-party fees that are directly associated with in-process equity issuances as deferred offering costs until such equity issuances are consummated. After consummation of the equity issuance, these costs are recorded as a reduction in the capitalized amount associated with the equity issuance. Should the equity issuance be delayed or abandoned, the deferred offering costs will be expensed immediately as a charge to operating expenses in the Company’s statement of operations. As of December 31, 2024, the Company incurred $1,377 of deferred offering costs related to the Company’s pending equity line of credit (“ELOC”) offering. During the year ended December 31, 2025, the Company issued common shares with a fair value of $328 related to the ELOC. The Company’s registration statement registering the ELOC was declared effective on April 24, 2025, and the Company will amortize these costs as cost of capital as funds are raised, based upon the Company’s estimate of the ultimate funds raised under the ELOC. During the year ended December 31, 2025, $614 of deferred offering costs were amortized as cost of capital, and as of December 31, 2025, total deferred offering costs were $1,091 related to the ELOC. Fair Value Measurements The Company determines the fair value of its assets and liabilities based on the exchange price in U.S. dollars that would be received to sell an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value maximize the use of observable inputs and minimize the use of unobservable inputs. The Company uses a fair value hierarchy with three levels of inputs, of which the first two are considered observable and the last unobservable, to measure fair value: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 1 — Quoted prices in active markets for identical assets or liabilities.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 2 — Inputs, other than Level 1, that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</td></tr> </table> The carrying amounts of financial instruments such as cash, and accounts payable and accrued liabilities, approximate the related fair values due to the short-term maturities of these instruments. Cash equivalents consisted of money market funds at December 31, 2025. Money market funds were valued by the Company using quoted prices in active markets for identical securities, which represent a Level 1 measurement within the fair value hierarchy. Income Taxes Income tax expense is based on pretax financial accounting income. Deferred tax assets and liabilities are recognized for the expected tax consequences of temporary differences between the tax bases of assets and liabilities and their reported amounts. Valuation allowances are recorded to reduce deferred tax assets to the amount that will more likely than not be realized. The Company recorded a 100% valuation allowance against its deferred tax assets as of December 31, 2025 and 2024. The Company accounts for uncertainty in income taxes using a two-step approach to recognize and measure uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50 percent likely of being realized upon settlement. The Company classifies the liability for unrecognized tax benefits as current to the extent that the Company anticipates payment (or receipt) of cash within one year. Interest and penalties related to uncertain tax positions are recognized in the provision for income taxes. Patents and Patent Application Costs Although the Company believes that its patents and underlying technology have continuing value, the amount of future benefits to be derived from the patents is uncertain. Patent costs are therefore expensed as incurred and are included in general and administrative expenses on the accompanying consolidated Statements of Operations. Patent expenses were $79 and $134 during the years ended December 31, 2025 and 2024. Research and Development Costs The Company expenses its research and development costs as incurred. Research and developments costs for the years ended December 31, 2025 and 2024 were $2,135 and $414, respectively. Research Contract Costs and Accruals The Company has entered into various research and development-related contracts with companies inside the United States. These agreements are generally cancellable, and related costs are recorded as research and development expenses as incurred. The Company records accruals for estimated ongoing research costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the studies or clinical trials, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the accrued balances at the end of any reporting period. Actual results could differ from the Company’s estimates. The Company’s historical accrual estimates have not been materially different from the actual costs. Stock-Based Compensation The Company measures all stock options, certain warrants and other stock-based awards granted based on the fair value of the award on the date of the grant and recognizes compensation expense for those awards over the requisite service period, which is generally the vesting period of the respective award. The Company has elected to recognize forfeitures as they occur. The reversal of compensation cost previously recognized for an award that is forfeited because of a failure to satisfy a service or performance condition is recognized in the period of the forfeiture. Generally, the Company issues stock options with only service-based vesting conditions and records the expense for these awards using the straight-line method over the requisite service period. The Company classifies stock-based compensation expense in its statements of operations in the same manner in which the award recipient’s payroll costs are classified or in which the award recipients’ service payments are classified. The Company was a private company until the completion of its IPO on September 17, 2024. Prior to the IPO, the Company estimated the fair value of common stock using an appropriate valuation methodology, in accordance with the framework of the American Institute of Certified Public Accountants’ Technical Practice Aid, Valuation of Privately-Held Company Equity Securities Issued as Compensation. Each valuation methodology includes estimates and assumptions that require the Company’s judgment. These estimates and assumptions include a number of objective and subjective factors, including external market conditions, guideline public company information, the prices at which the Company sold its common stock to third parties in arms’ length transactions, the rights and preferences of securities senior to the Company’s common stock at the time, and the likelihood of achieving a liquidity event such as an initial public offering or sale. Significant changes to the assumptions used in the valuations could result in different fair values of stock options or warrants at each valuation date, as applicable. Subsequent to September 17, 2024, the Company estimates the fair value of common stock based on its historical trading price at the date of grants. The fair value of each stock option or warrant grant is estimated using the Black-Scholes option-pricing model. Until the completion of its IPO, the Company was a private company and lacked company-specific historical and implied volatility information. Therefore, it estimated its expected stock volatility based on the historical volatility of a publicly traded set of peer companies within the biotechnology industry with characteristics similar to the Company. The expected term of the Company’s stock options has been determined utilizing the “simplified” method for awards that qualify as “plain-vanilla” options or warrants. The expected term of stock options or warrants granted to non-employees is equal to the contractual term of the option award. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield is zero, based on the fact that the Company has never paid cash dividends and does not expect to pay any cash dividends in the foreseeable future. Warrant Instruments The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the instruments’ specific terms and applicable authoritative guidance in ASC 480 and ASC 815. The assessment considers whether the instruments are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the instruments meet all of the requirements for equity classification under ASC 815, including whether the instruments are indexed to the Company’s own common stock and whether the instrument holders could potentially require net cash settlement in a circumstance outside of the Company’s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and, for liability-classified warrants, at each reporting period end date while the warrants are outstanding. Marketing and Advertising Costs Marketing and advertising expenses were not material for the years ended December 31, 2025 and 2024. Recent Accounting Pronouncements In November 2024, FASB issued ASU 2024-03 Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40) Disaggregation of Income Statement Expenses. The guidance in ASU 2024-03 requires public business entities to disclose in the notes to the financial statements, among other things, specific information about certain costs and expenses including purchases of inventory; employee compensation; and depreciation and amortization expense for each caption on the income statement where such expenses are included. The update is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted, and the amendments may be applied prospectively to reporting periods after the effective date or retrospectively to all periods presented in the financial statements. We are currently evaluating the provisions of this guidance and assessing the potential impact on our financial statement disclosures. Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company’s present or future consolidated financial statements.

Basis of Consolidation The accompanying consolidated financial statements and accompanying notes have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). The accompanying consolidated financial statements include the accounts of the Company and its former wholly-owned subsidiary, Enviro Therapeutics, Inc. (“Enviro”) which was dissolved in October 2025. All intercompany balances and transactions have been eliminated in consolidation.

Use of Estimates The preparation of the financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the financial statement date and reported amounts of revenue and expenses during the reporting period. Significant estimates are used in the valuation of accruals for potential liabilities, amortization of vendor advances and deferred offering costs, valuations of stock-based compensation, the realization of deferred tax assets, and impairment analysis and useful life for intangible assets among others. Actual results could differ from these estimates.

Concentration of Credit Risk Financial instruments, which potentially subject the Company to concentration of credit risk, consist primarily of cash deposits. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. Management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. The Company has not experienced any losses on deposits since its inception.

Cash Equivalents The Company considers all highly liquid investments with original maturities of three months or less on the date of purchase to be cash equivalents. The Company’s cash equivalents consisted of $4,326 in money market funds as of December 31, 2025. There were no cash equivalents as of December 31, 2024. The underlying securities in the money market funds held by the Company are all government backed securities.

4326000

Intangible Assets The Company’s intangible assets are stated at fair value as of the date acquired, less accumulated amortization. Amortization is calculated based on the estimated useful lives of the assets, which were determined to be five years, using the straight-line method. The intangible asset consists of a licensing agreement that the Company acquired through its acquisition of Enviro during the year ended December 31, 2021, with an acquisition cost of $<span id="xdx_90F_eus-gaap--BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_iI_pn3n3_c20211231__us-gaap--BusinessAcquisitionAxis__custom--EnviroThreapeuticsIncMember_z03lWFWQPhf7" title="Acquisition cost">800. Amortization expense relating to the intangible asset during the years ended December 31, 2025 and 2024 was $160, with an unamortized balance of $62 and $222 at December 31, 2025 and 2024, respectively.

P5Y

800000

160000

62000

222000

Impairment of Long-Lived Assets The Company applies the provisions of ASC Topic 360, Property, Plant, and Equipment, which addresses financial accounting and reporting for the impairment of long-lived assets. A long-lived asset that is held and used should be tested for recoverability whenever events or changes in circumstances indicate that the carrying amount of the asset group may not be recoverable. If the estimated undiscounted future cash flows are less than the carrying value, an impairment determination is required. In that event, a loss is recognized based on the amount by which the carrying amount exceeds the fair value of the long-lived assets. No impairment was recorded relating to the Company’s intangible asset during the years ended December 31, 2025 and 2024.

Income (Loss) Per Share Basic loss per share is computed by dividing net loss applicable to common stockholders by the weighted average number of outstanding common shares during the period. Shares of restricted stock are included in the basic weighted average number of common shares outstanding from the time they vest. Diluted loss per share is computed by dividing the net loss applicable to common stockholders by the weighted average number of common shares outstanding plus the number of additional common shares that would have been outstanding if all dilutive potential common shares had been issued. <p id="xdx_895_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zWBC5khKxgC1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">For the years ended December 31, 2025 and 2024, the basic and diluted shares outstanding were the same, as potentially dilutive shares were considered anti-dilutive. The potentially dilutive securities consisted of the following: SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49A_20250101__20251231_ztrOqxIRJUo" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20240101__20241231_zWrdaWbwoZt2" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_405_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsToPurchaseCommonStockMember_zSdwG3fjWBld" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: justify">Warrants to purchase common stock</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 18%; text-align: right">4,281,038</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 18%; text-align: right">278,188</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_z6cLrSkqe64d" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">Restricted stock units</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">772,605</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">172,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zM0KPOzyAVxa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">5,053,643</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">450,188</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

<p id="xdx_895_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zWBC5khKxgC1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">For the years ended December 31, 2025 and 2024, the basic and diluted shares outstanding were the same, as potentially dilutive shares were considered anti-dilutive. The potentially dilutive securities consisted of the following: SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49A_20250101__20251231_ztrOqxIRJUo" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20240101__20241231_zWrdaWbwoZt2" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_405_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsToPurchaseCommonStockMember_zSdwG3fjWBld" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: justify">Warrants to purchase common stock</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 18%; text-align: right">4,281,038</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 18%; text-align: right">278,188</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_z6cLrSkqe64d" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">Restricted stock units</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">772,605</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">172,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zM0KPOzyAVxa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">5,053,643</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">450,188</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

4281038

278188

772605

172000

5053643

450188

Deferred Offering Costs The Company capitalizes certain legal, professional, accounting and other third-party fees that are directly associated with in-process equity issuances as deferred offering costs until such equity issuances are consummated. After consummation of the equity issuance, these costs are recorded as a reduction in the capitalized amount associated with the equity issuance. Should the equity issuance be delayed or abandoned, the deferred offering costs will be expensed immediately as a charge to operating expenses in the Company’s statement of operations. As of December 31, 2024, the Company incurred $1,377 of deferred offering costs related to the Company’s pending equity line of credit (“ELOC”) offering. During the year ended December 31, 2025, the Company issued common shares with a fair value of $328 related to the ELOC. The Company’s registration statement registering the ELOC was declared effective on April 24, 2025, and the Company will amortize these costs as cost of capital as funds are raised, based upon the Company’s estimate of the ultimate funds raised under the ELOC. During the year ended December 31, 2025, $614 of deferred offering costs were amortized as cost of capital, and as of December 31, 2025, total deferred offering costs were $1,091 related to the ELOC.

1377000

328000

614000

1091000

Fair Value Measurements The Company determines the fair value of its assets and liabilities based on the exchange price in U.S. dollars that would be received to sell an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value maximize the use of observable inputs and minimize the use of unobservable inputs. The Company uses a fair value hierarchy with three levels of inputs, of which the first two are considered observable and the last unobservable, to measure fair value: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 1 — Quoted prices in active markets for identical assets or liabilities.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 2 — Inputs, other than Level 1, that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</td></tr> </table> The carrying amounts of financial instruments such as cash, and accounts payable and accrued liabilities, approximate the related fair values due to the short-term maturities of these instruments. Cash equivalents consisted of money market funds at December 31, 2025. Money market funds were valued by the Company using quoted prices in active markets for identical securities, which represent a Level 1 measurement within the fair value hierarchy.

Income Taxes Income tax expense is based on pretax financial accounting income. Deferred tax assets and liabilities are recognized for the expected tax consequences of temporary differences between the tax bases of assets and liabilities and their reported amounts. Valuation allowances are recorded to reduce deferred tax assets to the amount that will more likely than not be realized. The Company recorded a 100% valuation allowance against its deferred tax assets as of December 31, 2025 and 2024. The Company accounts for uncertainty in income taxes using a two-step approach to recognize and measure uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50 percent likely of being realized upon settlement. The Company classifies the liability for unrecognized tax benefits as current to the extent that the Company anticipates payment (or receipt) of cash within one year. Interest and penalties related to uncertain tax positions are recognized in the provision for income taxes.

1 1 Patents and Patent Application Costs Although the Company believes that its patents and underlying technology have continuing value, the amount of future benefits to be derived from the patents is uncertain. Patent costs are therefore expensed as incurred and are included in general and administrative expenses on the accompanying consolidated Statements of Operations. Patent expenses were $79 and $134 during the years ended December 31, 2025 and 2024.

79000

134000

Research and Development Costs The Company expenses its research and development costs as incurred. Research and developments costs for the years ended December 31, 2025 and 2024 were $2,135 and $414, respectively.

2135000

414000

Research Contract Costs and Accruals The Company has entered into various research and development-related contracts with companies inside the United States. These agreements are generally cancellable, and related costs are recorded as research and development expenses as incurred. The Company records accruals for estimated ongoing research costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the studies or clinical trials, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the accrued balances at the end of any reporting period. Actual results could differ from the Company’s estimates. The Company’s historical accrual estimates have not been materially different from the actual costs.

Stock-Based Compensation The Company measures all stock options, certain warrants and other stock-based awards granted based on the fair value of the award on the date of the grant and recognizes compensation expense for those awards over the requisite service period, which is generally the vesting period of the respective award. The Company has elected to recognize forfeitures as they occur. The reversal of compensation cost previously recognized for an award that is forfeited because of a failure to satisfy a service or performance condition is recognized in the period of the forfeiture. Generally, the Company issues stock options with only service-based vesting conditions and records the expense for these awards using the straight-line method over the requisite service period. The Company classifies stock-based compensation expense in its statements of operations in the same manner in which the award recipient’s payroll costs are classified or in which the award recipients’ service payments are classified. The Company was a private company until the completion of its IPO on September 17, 2024. Prior to the IPO, the Company estimated the fair value of common stock using an appropriate valuation methodology, in accordance with the framework of the American Institute of Certified Public Accountants’ Technical Practice Aid, Valuation of Privately-Held Company Equity Securities Issued as Compensation. Each valuation methodology includes estimates and assumptions that require the Company’s judgment. These estimates and assumptions include a number of objective and subjective factors, including external market conditions, guideline public company information, the prices at which the Company sold its common stock to third parties in arms’ length transactions, the rights and preferences of securities senior to the Company’s common stock at the time, and the likelihood of achieving a liquidity event such as an initial public offering or sale. Significant changes to the assumptions used in the valuations could result in different fair values of stock options or warrants at each valuation date, as applicable. Subsequent to September 17, 2024, the Company estimates the fair value of common stock based on its historical trading price at the date of grants. The fair value of each stock option or warrant grant is estimated using the Black-Scholes option-pricing model. Until the completion of its IPO, the Company was a private company and lacked company-specific historical and implied volatility information. Therefore, it estimated its expected stock volatility based on the historical volatility of a publicly traded set of peer companies within the biotechnology industry with characteristics similar to the Company. The expected term of the Company’s stock options has been determined utilizing the “simplified” method for awards that qualify as “plain-vanilla” options or warrants. The expected term of stock options or warrants granted to non-employees is equal to the contractual term of the option award. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield is zero, based on the fact that the Company has never paid cash dividends and does not expect to pay any cash dividends in the foreseeable future.

Warrant Instruments The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the instruments’ specific terms and applicable authoritative guidance in ASC 480 and ASC 815. The assessment considers whether the instruments are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the instruments meet all of the requirements for equity classification under ASC 815, including whether the instruments are indexed to the Company’s own common stock and whether the instrument holders could potentially require net cash settlement in a circumstance outside of the Company’s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and, for liability-classified warrants, at each reporting period end date while the warrants are outstanding.

Marketing and Advertising Costs Marketing and advertising expenses were not material for the years ended December 31, 2025 and 2024.

Recent Accounting Pronouncements In November 2024, FASB issued ASU 2024-03 Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40) Disaggregation of Income Statement Expenses. The guidance in ASU 2024-03 requires public business entities to disclose in the notes to the financial statements, among other things, specific information about certain costs and expenses including purchases of inventory; employee compensation; and depreciation and amortization expense for each caption on the income statement where such expenses are included. The update is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted, and the amendments may be applied prospectively to reporting periods after the effective date or retrospectively to all periods presented in the financial statements. We are currently evaluating the provisions of this guidance and assessing the potential impact on our financial statement disclosures. Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company’s present or future consolidated financial statements.

NOTE 3 – VENDOR AGREEMENTS Vendor Advances The Company has entered into various contracts with service providers pursuant to which the Company pays the vendor an advance at the beginning of the contractual period. These vendor advances could be paid by the Company either in cash or in shares of common stock, depending on the terms of the contract. The advances are reduced by the accumulated value of the services performed by the vendor or are amortized on a straight-line basis over the service period, whichever is shorter. As of December 31, 2024, advances to vendors totaled $3,115, with $2,615 being paid in cash and $500 being paid with shares of the Company’s common stock. Amortization expense relating to the vendor advances during the year ended December 31, 2024 was $256, with an unamortized balance of $2,859 as of December 31, 2024. During the year ended December 31, 2025, an additional advance to a vendor totaled $156, with the advance being paid with shares of the Company’s common stock, and amortization expense relating to the vendor advances was $2,170, with an unamortized balance of $845 as of December 31, 2025. Vendor advances consisted of the following at December 31, 2025, and 2024: SCHEDULE OF VENDOR ADVANCES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20251231_zCI8vh6X3aX5" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20241231_zIbfl4yWeSW7" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_40F_ecustom--VendorAdvancesGross_iI_pn3n3_hdei--LegalEntityAxis__custom--PrevailInfoworksIncMember_zAPVMqqIRFP" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: justify">Prevail Infoworks (a)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">900</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">900</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_ecustom--VendorAdvancesGross_iI_pn3n3_hdei--LegalEntityAxis__custom--PreCheckHealthServicesIncMember_zTTleUnKEdk8" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">PreCheck Health Services (b)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">900</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">900</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_ecustom--VendorAdvancesGross_iI_pn3n3_hdei--LegalEntityAxis__custom--CEOCATechnologiesLtdMember_zTERziNDovI4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">CEO.CA Technologies (c)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">250</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">250</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--VendorAdvancesGross_iI_pn3n3_hdei--LegalEntityAxis__custom--BelairCapitalAdvisorsIncMember_zcU4DyGtHvcb" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Belair Capital Advisors (d)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">365</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">365</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_ecustom--VendorAdvancesGross_iI_pn3n3_hdei--LegalEntityAxis__custom--CrossCurrentCapitalLLCMember_zhqBid8nE0Sl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1pt">Cross Current Capital (e)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">856</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">700</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40F_ecustom--VendorAdvancesGross_iI_pn3n3_maVANzK0F_z1IedTKfsTC3" style="vertical-align: bottom; background-color: White"> <td>Vendor advances, gross</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,271</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,115</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--VendorAdvancesAccumulatedAmortization_iNI_pn3n3_di_msVANzK0F_zdBYr5C4u1ke" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1pt">Less: accumulated amortization</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(2,426</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(256</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_404_ecustom--VendorAdvancesNet_iTI_pn3n3_mtVANzK0F_zVRJmKNCnVMd" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Vendor advances, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">845</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,859</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> The remaining unamortized balance of $845 as of December 31, 2025, will be fully amortized during the year ending December 31, 2026. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">(a)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Kairos Agreement with Prevail Infoworks, Inc.</td></tr> </table> On August 1, 2024, the Company entered into a master service and technology agreement with Prevail Infoworks, Inc. (“Prevail”), pursuant to which Prevail agreed to provide certain clinical research services to the Company. As part of the agreement, the Company was required to make an advance payment of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFZFTkRPUiBBRFZBTkNFUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_905_eus-gaap--PaymentsForAdvanceToAffiliate_pn3n3_c20240801__20240801__us-gaap--TypeOfArrangementAxis__custom--MasterServiceAndTechnologyAgreementMember_zD5wwmeCYk4j" title="Advance payment">900 to Prevail before commencement of services and, at such time as we notify Prevail to engage their services related to the relevant clinical trial, or six months from the date of the agreement, pay approximately $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFZFTkRPUiBBRFZBTkNFUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_908_ecustom--MonthlyPayment_pn3n3_c20240801__20240801__us-gaap--TypeOfArrangementAxis__custom--MasterServiceAndTechnologyAgreementMember_z6OepIWoHEIe" title="Monthly payment">80 per month during the time Prevail performs clinical research services for the Company’s Phase 2 ENV 105 prostate and Phase 1 ENV 105 lung clinical trials. The agreement with Prevail is subject to cancellation at any time upon 30 days’ written notice to the other party. The Company made the advance payment to Prevail in October 2024 and it is included in vendor advances on the accompanying Balance Sheet as of December 31, 2025 and 2024. The unamortized balance of the advance was $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFZFTkRPUiBBRFZBTkNFUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_908_eus-gaap--DebtInstrumentUnamortizedPremium_iI_pn3n3_c20251231__us-gaap--TypeOfArrangementAxis__custom--MasterServiceAndTechnologyAgreementMember_zZiOtijrf2ug" title="Unamortizaed balance">500 as of December 31, 2025. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">(b)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Kairos Agreement with PreCheck Health Services, Inc.</td></tr> </table> On September 20, 2024, the Company entered into a bioassay services agreement (the “Bioassay Services Agreement”) with PreCheck Health Services, Inc., a Florida-based corporation (“PreCheck”). Pursuant to the Bioassay Services Agreement, PreCheck will provide certain biomarker screening services for the Company’s ongoing carotuximab (ENV105) clinical trials in order to assist the Company in identifying lung and prostate cancer patients suitable to the Company’s ongoing Phase 1 clinical trials for lung cancer patients and Phase 2 clinical trials for patients with castrate resistant prostate cancer. In exchange for PreCheck’s services, and according to the terms of the Bioassay Services Agreement, the Company paid $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFZFTkRPUiBBRFZBTkNFUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_905_eus-gaap--PaymentsForAdvanceToAffiliate_pn3n3_c20240920__20240920__us-gaap--TypeOfArrangementAxis__custom--BioassayServicesAgreementMember__dei--LegalEntityAxis__custom--PreCheckHealthServicesIncMember_zGUQKO8qewL8" title="Payments for services">900 to PreCheck as an advance for the future laboratory services to be performed. The payment of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFZFTkRPUiBBRFZBTkNFUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_900_eus-gaap--PaymentsForAdvanceToAffiliate_pn3n3_c20250101__20251231__us-gaap--TypeOfArrangementAxis__custom--BioassayServicesAgreementMember__dei--LegalEntityAxis__custom--PreCheckHealthServicesIncMember_zZVIkLUUKD52" title="Payments for vendor advance"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFZFTkRPUiBBRFZBTkNFUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90E_eus-gaap--PaymentsForAdvanceToAffiliate_pn3n3_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--BioassayServicesAgreementMember__dei--LegalEntityAxis__custom--PreCheckHealthServicesIncMember_z67xNEhV9Rgg" title="Payments for vendor advance">900 is included in vendor advances on the accompanying Balance Sheet as of December 31, 2025 and 2024. The term of the agreement is one year from the effective date. The advance was fully amortized as of December 31, 2025. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">(c)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Kairos Agreement with CEO.CA Technologies Ltd.</td></tr> </table> On September 23, 2024, the Company entered into an advisory and consulting services agreement (the “CEO.CA Agreement”) with CEO.CA Technologies Ltd., a Canadian company (“CEO.CA”), pursuant to which CEO.CA will provide certain internet-based financial information and communications services for a period of one year for a services fee of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFZFTkRPUiBBRFZBTkNFUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_901_eus-gaap--ManagementFeeExpense_pn3n3_c20240923__20240923__us-gaap--TypeOfArrangementAxis__custom--AdvisoryAndConsultingServicesAgreementMember__dei--LegalEntityAxis__custom--CEOCATechnologiesLtdMember_ziEpoZpmoT29" title="Service fee">250. The service fee is an advance on future services to be performed. The CEO.CA Agreement includes services such as strategic news placement, news releases, interviews, monthly analytics and a video launch. The CEO.CA Agreement contains other customary clauses, including representations and warranties, indemnification clauses and governing law clauses. The payment of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFZFTkRPUiBBRFZBTkNFUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_907_eus-gaap--ManagementFeeExpense_pn3n3_c20250101__20251231__us-gaap--TypeOfArrangementAxis__custom--AdvisoryAndConsultingServicesAgreementMember__dei--LegalEntityAxis__custom--CEOCATechnologiesLtdMember_zCIhN3IgWYXe" title="Service fee"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFZFTkRPUiBBRFZBTkNFUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_905_eus-gaap--ManagementFeeExpense_pn3n3_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--AdvisoryAndConsultingServicesAgreementMember__dei--LegalEntityAxis__custom--CEOCATechnologiesLtdMember_zjrjCGXiVGQe" title="Service fee">250 is included in vendor advances on the accompanying Balance Sheet as of December 31, 2025 and 2024. The advance was fully amortized as of December 31, 2025. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">(d)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Kairos Agreement with Belair Capital Advisors Inc.</td></tr> </table> On September 23, 2024, the Company entered into a strategic advisory agreement (the “Strategic Advisory Agreement”) with Belair Capital Advisors Inc. (“BCA”). BCA, a venture capital and corporate finance advisory firm, has been a long-term investor and advisor to the Company and frequently works with early-stage pharmaceutical companies. The strategic advisory services provided by BCA consist of corporate strategy, market positioning and long-term growth plans within the pharmaceutical sector, digital marketing and engagement, market research analysis and business development assistance, among other things. During the one-year term of the Strategic Advisory Agreement, in exchange for its services, the Company will pay BCA a $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFZFTkRPUiBBRFZBTkNFUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90A_eus-gaap--ManagementFeeExpense_pn3n3_c20240923__20240923__us-gaap--TypeOfArrangementAxis__custom--StrategicAdvisoryAgreementMember__dei--LegalEntityAxis__custom--BelairCapitalAdvisorsIncMember_zsLtyAEtnaah" title="Service fee">365 fee and will issue BCA <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFZFTkRPUiBBRFZBTkNFUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pid_c20240923__20240923__us-gaap--TypeOfArrangementAxis__custom--StrategicAdvisoryAgreementMember__dei--LegalEntityAxis__custom--BelairCapitalAdvisorsIncMember_z8jSFRaktJUb" title="Number of shares issued">50,000 RSUs, which will vest at the end of six months following the date of issuance. The payment of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFZFTkRPUiBBRFZBTkNFUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_901_eus-gaap--ManagementFeeExpense_pn3n3_c20250101__20251231__us-gaap--TypeOfArrangementAxis__custom--StrategicAdvisoryAgreementMember__dei--LegalEntityAxis__custom--BelairCapitalAdvisorsIncMember_zYgV6hnVkZFg" title="Service fee"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFZFTkRPUiBBRFZBTkNFUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_900_eus-gaap--ManagementFeeExpense_pn3n3_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--StrategicAdvisoryAgreementMember__dei--LegalEntityAxis__custom--BelairCapitalAdvisorsIncMember_z30MRoq4QLQb" title="Service fee">365 is included in vendor advances on the accompanying Balance Sheet as of December 31, 2025 and 2024. The advance was fully amortized as of December 31, 2025. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">(e)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Kairos Agreement with Cross Current Capital LLC</td></tr> </table> On October 1, 2024, the Company entered into a consulting agreement (the “Consulting Agreement”) with Cross Current Capital LLC, a limited liability company organized under the laws of Puerto Rico (“Cross Current”), and Alan Masley (the “Advisor”), pursuant to which Cross Current agreed to provide certain financial and business consulting services to the Company including, but not limited, to (a) help drafting a public company competitive overview, (b) help preparing and/or reviewing a valuation analysis, (c) help in drafting marketing materials and presentations, (d) reviewing the Company’s business requirements and discuss financing and businesses opportunities, (e) investor marketing, (f) investor relations introductions, (g) legal counsel introductions, (h) auditor introductions, (i) investment banking and research introductions, (j) M&A canvassing and ways to grow the business organically, and (k) stand by capital markets advisory services. For the services rendered thereunder, the Company agreed to pay Cross Current $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFZFTkRPUiBBRFZBTkNFUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_908_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn3n3_c20241001__20241001__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zU9RJB4HgqJ9">200 in cash and agreed to issue to the Advisor $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFZFTkRPUiBBRFZBTkNFUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_pn3n3_c20241001__20241001__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zlhOC8VZGrH9" title="Numbr of RSU issued">500 of restricted shares of the Company’s common stock under the Company’s 2023 Plan, which was calculated at <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFZFTkRPUiBBRFZBTkNFUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20241001__20241001__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_ziuUXMXnp7v9">367,647 shares (the “Shares”) as of the date of the agreement and were issuable at December 31, 2024. The term of the Consulting Agreement is 24 months and can be extended for another 12 months upon the written consent of both parties. The Company made the $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFZFTkRPUiBBRFZBTkNFUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_900_ecustom--SettlementAgreementAmount_pn3n3_c20241001__20241001__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zpxcWgqnXFD6">200 payment in October 2024. The payment of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFZFTkRPUiBBRFZBTkNFUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_905_ecustom--VendorPaymentAdvances_iI_pn3n3_c20251231__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zor8Ui7J4iu3"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFZFTkRPUiBBRFZBTkNFUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90F_ecustom--VendorPaymentAdvances_iI_pn3n3_c20241231__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zM2bGbsy0bia">200 and the value of the shares issued of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFZFTkRPUiBBRFZBTkNFUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90D_eus-gaap--AdditionalCollateralAggregateFairValue_iI_pn3n3_c20251231__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zhEYrVMcCoOl"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFZFTkRPUiBBRFZBTkNFUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_900_eus-gaap--AdditionalCollateralAggregateFairValue_iI_pn3n3_c20241231__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_znayAn9dtQya">500 are included in vendor advances on the accompanying Balance Sheet as of December 31, 2025 and 2024. The <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFZFTkRPUiBBRFZBTkNFUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250401__20250401__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zzNNrNKZs435" title="Stock issued shares">367,647 shares issuable in 2024 were subject to a “true up” on April 1, 2025, at which time additional shares were either issuable to the Advisor or to be returned by the Advisor to the Company in order to ensure the shares were valued at $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFZFTkRPUiBBRFZBTkNFUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn3n3_c20250401__20250401__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zCFov1QBTFK2" title="Number of shares issued, value">500 as of April 1, 2025. Accordingly, on April 1, 2025, the Company issued an additional <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFZFTkRPUiBBRFZBTkNFUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250401__20250401__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zYmRDZzkH6m8" title="Number of shares issued">166,541 shares of its common stock to the Advisor to bring the value to $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFZFTkRPUiBBRFZBTkNFUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn3n3_c20250401__20250401__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zKDLWhiMjJM6" title="Number of shares issued, value">500. All the issuable shares were issued during the year ended December 31, 2025. The fair value of the additional shares on the date of grant was $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFZFTkRPUiBBRFZBTkNFUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_903_ecustom--FairValueOfAdditionalSharesOnGrantDate_pn3n3_c20250401__20250401__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zoG5ljLjwfQf" title="Fair value of additional shares on grant date">156. The Company recorded the fair value of the shares as a vendor advance as of the same date. The unamortized balance of the advance was $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFZFTkRPUiBBRFZBTkNFUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_909_eus-gaap--DebtInstrumentUnamortizedPremium_iI_pn3n3_c20251231__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zHnn0r6rf8x6" title="Unamortizaed balance">345 at December 31, 2025.

3115000

-2615000 500000 256000 2859000 156000 2170000 845000 Vendor advances consisted of the following at December 31, 2025, and 2024: SCHEDULE OF VENDOR ADVANCES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20251231_zCI8vh6X3aX5" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20241231_zIbfl4yWeSW7" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2024</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_40F_ecustom--VendorAdvancesGross_iI_pn3n3_hdei--LegalEntityAxis__custom--PrevailInfoworksIncMember_zAPVMqqIRFP" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: justify">Prevail Infoworks (a)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">900</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">900</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_ecustom--VendorAdvancesGross_iI_pn3n3_hdei--LegalEntityAxis__custom--PreCheckHealthServicesIncMember_zTTleUnKEdk8" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">PreCheck Health Services (b)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">900</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">900</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_ecustom--VendorAdvancesGross_iI_pn3n3_hdei--LegalEntityAxis__custom--CEOCATechnologiesLtdMember_zTERziNDovI4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">CEO.CA Technologies (c)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">250</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">250</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--VendorAdvancesGross_iI_pn3n3_hdei--LegalEntityAxis__custom--BelairCapitalAdvisorsIncMember_zcU4DyGtHvcb" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Belair Capital Advisors (d)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">365</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">365</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_ecustom--VendorAdvancesGross_iI_pn3n3_hdei--LegalEntityAxis__custom--CrossCurrentCapitalLLCMember_zhqBid8nE0Sl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1pt">Cross Current Capital (e)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">856</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">700</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40F_ecustom--VendorAdvancesGross_iI_pn3n3_maVANzK0F_z1IedTKfsTC3" style="vertical-align: bottom; background-color: White"> <td>Vendor advances, gross</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,271</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,115</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--VendorAdvancesAccumulatedAmortization_iNI_pn3n3_di_msVANzK0F_zdBYr5C4u1ke" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1pt">Less: accumulated amortization</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(2,426</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(256</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_404_ecustom--VendorAdvancesNet_iTI_pn3n3_mtVANzK0F_zVRJmKNCnVMd" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Vendor advances, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">845</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,859</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> The remaining unamortized balance of $845 as of December 31, 2025, will be fully amortized during the year ending December 31, 2026. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">(a)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Kairos Agreement with Prevail Infoworks, Inc.</td></tr> </table> On August 1, 2024, the Company entered into a master service and technology agreement with Prevail Infoworks, Inc. (“Prevail”), pursuant to which Prevail agreed to provide certain clinical research services to the Company. As part of the agreement, the Company was required to make an advance payment of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFZFTkRPUiBBRFZBTkNFUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_905_eus-gaap--PaymentsForAdvanceToAffiliate_pn3n3_c20240801__20240801__us-gaap--TypeOfArrangementAxis__custom--MasterServiceAndTechnologyAgreementMember_zD5wwmeCYk4j" title="Advance payment">900 to Prevail before commencement of services and, at such time as we notify Prevail to engage their services related to the relevant clinical trial, or six months from the date of the agreement, pay approximately $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFZFTkRPUiBBRFZBTkNFUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_908_ecustom--MonthlyPayment_pn3n3_c20240801__20240801__us-gaap--TypeOfArrangementAxis__custom--MasterServiceAndTechnologyAgreementMember_z6OepIWoHEIe" title="Monthly payment">80 per month during the time Prevail performs clinical research services for the Company’s Phase 2 ENV 105 prostate and Phase 1 ENV 105 lung clinical trials. The agreement with Prevail is subject to cancellation at any time upon 30 days’ written notice to the other party. The Company made the advance payment to Prevail in October 2024 and it is included in vendor advances on the accompanying Balance Sheet as of December 31, 2025 and 2024. The unamortized balance of the advance was $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFZFTkRPUiBBRFZBTkNFUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_908_eus-gaap--DebtInstrumentUnamortizedPremium_iI_pn3n3_c20251231__us-gaap--TypeOfArrangementAxis__custom--MasterServiceAndTechnologyAgreementMember_zZiOtijrf2ug" title="Unamortizaed balance">500 as of December 31, 2025. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">(b)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Kairos Agreement with PreCheck Health Services, Inc.</td></tr> </table> On September 20, 2024, the Company entered into a bioassay services agreement (the “Bioassay Services Agreement”) with PreCheck Health Services, Inc., a Florida-based corporation (“PreCheck”). Pursuant to the Bioassay Services Agreement, PreCheck will provide certain biomarker screening services for the Company’s ongoing carotuximab (ENV105) clinical trials in order to assist the Company in identifying lung and prostate cancer patients suitable to the Company’s ongoing Phase 1 clinical trials for lung cancer patients and Phase 2 clinical trials for patients with castrate resistant prostate cancer. In exchange for PreCheck’s services, and according to the terms of the Bioassay Services Agreement, the Company paid $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFZFTkRPUiBBRFZBTkNFUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_905_eus-gaap--PaymentsForAdvanceToAffiliate_pn3n3_c20240920__20240920__us-gaap--TypeOfArrangementAxis__custom--BioassayServicesAgreementMember__dei--LegalEntityAxis__custom--PreCheckHealthServicesIncMember_zGUQKO8qewL8" title="Payments for services">900 to PreCheck as an advance for the future laboratory services to be performed. The payment of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFZFTkRPUiBBRFZBTkNFUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_900_eus-gaap--PaymentsForAdvanceToAffiliate_pn3n3_c20250101__20251231__us-gaap--TypeOfArrangementAxis__custom--BioassayServicesAgreementMember__dei--LegalEntityAxis__custom--PreCheckHealthServicesIncMember_zZVIkLUUKD52" title="Payments for vendor advance"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFZFTkRPUiBBRFZBTkNFUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90E_eus-gaap--PaymentsForAdvanceToAffiliate_pn3n3_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--BioassayServicesAgreementMember__dei--LegalEntityAxis__custom--PreCheckHealthServicesIncMember_z67xNEhV9Rgg" title="Payments for vendor advance">900 is included in vendor advances on the accompanying Balance Sheet as of December 31, 2025 and 2024. The term of the agreement is one year from the effective date. The advance was fully amortized as of December 31, 2025. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">(c)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Kairos Agreement with CEO.CA Technologies Ltd.</td></tr> </table> On September 23, 2024, the Company entered into an advisory and consulting services agreement (the “CEO.CA Agreement”) with CEO.CA Technologies Ltd., a Canadian company (“CEO.CA”), pursuant to which CEO.CA will provide certain internet-based financial information and communications services for a period of one year for a services fee of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFZFTkRPUiBBRFZBTkNFUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_901_eus-gaap--ManagementFeeExpense_pn3n3_c20240923__20240923__us-gaap--TypeOfArrangementAxis__custom--AdvisoryAndConsultingServicesAgreementMember__dei--LegalEntityAxis__custom--CEOCATechnologiesLtdMember_ziEpoZpmoT29" title="Service fee">250. The service fee is an advance on future services to be performed. The CEO.CA Agreement includes services such as strategic news placement, news releases, interviews, monthly analytics and a video launch. The CEO.CA Agreement contains other customary clauses, including representations and warranties, indemnification clauses and governing law clauses. The payment of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFZFTkRPUiBBRFZBTkNFUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_907_eus-gaap--ManagementFeeExpense_pn3n3_c20250101__20251231__us-gaap--TypeOfArrangementAxis__custom--AdvisoryAndConsultingServicesAgreementMember__dei--LegalEntityAxis__custom--CEOCATechnologiesLtdMember_zCIhN3IgWYXe" title="Service fee"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFZFTkRPUiBBRFZBTkNFUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_905_eus-gaap--ManagementFeeExpense_pn3n3_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--AdvisoryAndConsultingServicesAgreementMember__dei--LegalEntityAxis__custom--CEOCATechnologiesLtdMember_zjrjCGXiVGQe" title="Service fee">250 is included in vendor advances on the accompanying Balance Sheet as of December 31, 2025 and 2024. The advance was fully amortized as of December 31, 2025. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">(d)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Kairos Agreement with Belair Capital Advisors Inc.</td></tr> </table> On September 23, 2024, the Company entered into a strategic advisory agreement (the “Strategic Advisory Agreement”) with Belair Capital Advisors Inc. (“BCA”). BCA, a venture capital and corporate finance advisory firm, has been a long-term investor and advisor to the Company and frequently works with early-stage pharmaceutical companies. The strategic advisory services provided by BCA consist of corporate strategy, market positioning and long-term growth plans within the pharmaceutical sector, digital marketing and engagement, market research analysis and business development assistance, among other things. During the one-year term of the Strategic Advisory Agreement, in exchange for its services, the Company will pay BCA a $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFZFTkRPUiBBRFZBTkNFUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90A_eus-gaap--ManagementFeeExpense_pn3n3_c20240923__20240923__us-gaap--TypeOfArrangementAxis__custom--StrategicAdvisoryAgreementMember__dei--LegalEntityAxis__custom--BelairCapitalAdvisorsIncMember_zsLtyAEtnaah" title="Service fee">365 fee and will issue BCA <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFZFTkRPUiBBRFZBTkNFUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pid_c20240923__20240923__us-gaap--TypeOfArrangementAxis__custom--StrategicAdvisoryAgreementMember__dei--LegalEntityAxis__custom--BelairCapitalAdvisorsIncMember_z8jSFRaktJUb" title="Number of shares issued">50,000 RSUs, which will vest at the end of six months following the date of issuance. The payment of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFZFTkRPUiBBRFZBTkNFUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_901_eus-gaap--ManagementFeeExpense_pn3n3_c20250101__20251231__us-gaap--TypeOfArrangementAxis__custom--StrategicAdvisoryAgreementMember__dei--LegalEntityAxis__custom--BelairCapitalAdvisorsIncMember_zYgV6hnVkZFg" title="Service fee"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFZFTkRPUiBBRFZBTkNFUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_900_eus-gaap--ManagementFeeExpense_pn3n3_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--StrategicAdvisoryAgreementMember__dei--LegalEntityAxis__custom--BelairCapitalAdvisorsIncMember_z30MRoq4QLQb" title="Service fee">365 is included in vendor advances on the accompanying Balance Sheet as of December 31, 2025 and 2024. The advance was fully amortized as of December 31, 2025. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">(e)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Kairos Agreement with Cross Current Capital LLC</td></tr> </table> On October 1, 2024, the Company entered into a consulting agreement (the “Consulting Agreement”) with Cross Current Capital LLC, a limited liability company organized under the laws of Puerto Rico (“Cross Current”), and Alan Masley (the “Advisor”), pursuant to which Cross Current agreed to provide certain financial and business consulting services to the Company including, but not limited, to (a) help drafting a public company competitive overview, (b) help preparing and/or reviewing a valuation analysis, (c) help in drafting marketing materials and presentations, (d) reviewing the Company’s business requirements and discuss financing and businesses opportunities, (e) investor marketing, (f) investor relations introductions, (g) legal counsel introductions, (h) auditor introductions, (i) investment banking and research introductions, (j) M&A canvassing and ways to grow the business organically, and (k) stand by capital markets advisory services. For the services rendered thereunder, the Company agreed to pay Cross Current $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFZFTkRPUiBBRFZBTkNFUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_908_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn3n3_c20241001__20241001__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zU9RJB4HgqJ9">200 in cash and agreed to issue to the Advisor $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFZFTkRPUiBBRFZBTkNFUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_pn3n3_c20241001__20241001__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zlhOC8VZGrH9" title="Numbr of RSU issued">500 of restricted shares of the Company’s common stock under the Company’s 2023 Plan, which was calculated at <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFZFTkRPUiBBRFZBTkNFUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20241001__20241001__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_ziuUXMXnp7v9">367,647 shares (the “Shares”) as of the date of the agreement and were issuable at December 31, 2024. The term of the Consulting Agreement is 24 months and can be extended for another 12 months upon the written consent of both parties. The Company made the $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFZFTkRPUiBBRFZBTkNFUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_900_ecustom--SettlementAgreementAmount_pn3n3_c20241001__20241001__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zpxcWgqnXFD6">200 payment in October 2024. The payment of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFZFTkRPUiBBRFZBTkNFUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_905_ecustom--VendorPaymentAdvances_iI_pn3n3_c20251231__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zor8Ui7J4iu3"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFZFTkRPUiBBRFZBTkNFUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90F_ecustom--VendorPaymentAdvances_iI_pn3n3_c20241231__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zM2bGbsy0bia">200 and the value of the shares issued of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFZFTkRPUiBBRFZBTkNFUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90D_eus-gaap--AdditionalCollateralAggregateFairValue_iI_pn3n3_c20251231__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zhEYrVMcCoOl"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFZFTkRPUiBBRFZBTkNFUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_900_eus-gaap--AdditionalCollateralAggregateFairValue_iI_pn3n3_c20241231__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_znayAn9dtQya">500 are included in vendor advances on the accompanying Balance Sheet as of December 31, 2025 and 2024. The <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFZFTkRPUiBBRFZBTkNFUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250401__20250401__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zzNNrNKZs435" title="Stock issued shares">367,647 shares issuable in 2024 were subject to a “true up” on April 1, 2025, at which time additional shares were either issuable to the Advisor or to be returned by the Advisor to the Company in order to ensure the shares were valued at $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFZFTkRPUiBBRFZBTkNFUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn3n3_c20250401__20250401__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zCFov1QBTFK2" title="Number of shares issued, value">500 as of April 1, 2025. Accordingly, on April 1, 2025, the Company issued an additional <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFZFTkRPUiBBRFZBTkNFUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250401__20250401__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zYmRDZzkH6m8" title="Number of shares issued">166,541 shares of its common stock to the Advisor to bring the value to $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFZFTkRPUiBBRFZBTkNFUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn3n3_c20250401__20250401__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zKDLWhiMjJM6" title="Number of shares issued, value">500. All the issuable shares were issued during the year ended December 31, 2025. The fair value of the additional shares on the date of grant was $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFZFTkRPUiBBRFZBTkNFUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_903_ecustom--FairValueOfAdditionalSharesOnGrantDate_pn3n3_c20250401__20250401__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zoG5ljLjwfQf" title="Fair value of additional shares on grant date">156. The Company recorded the fair value of the shares as a vendor advance as of the same date. The unamortized balance of the advance was $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFZFTkRPUiBBRFZBTkNFUyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_909_eus-gaap--DebtInstrumentUnamortizedPremium_iI_pn3n3_c20251231__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zHnn0r6rf8x6" title="Unamortizaed balance">345 at December 31, 2025. 900000 900000 900000 900000 250000 250000 365000 365000 856000 700000 3271000 3115000 2426000 256000 845000 2859000 845000

900000

80000

500000

900000

250000

365000

50000

365000

200000

500000

367647

200000 200000 200000

500000

367647

500000

166541

500000

156000

345000

NOTE 4 – DEFERRED OFFERING COSTS Agreement with Helena Global Investment Opportunities On November 12, 2024, the Company entered into an agreement with Helena Global Investment Opportunities I LTD (“Helena”) pursuant to which the Company will have the right to issue and sell to Helena, from time to time, and Helena shall purchase from the Company, up to $<span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn3n3_c20241112__20241112__dei--LegalEntityAxis__custom--HelenaGlobalInvestmentOpportunitiesILTDMember_zQCzU5B35pPa" title="Number of shares issued, value">30,000 of the Company’s shares of common stock (the “Equity Line of Credit”). The Equity Line of Credit became available to the Company after the Company filed a registration statement on Form S-1 registering the shares issuable under the Equity Line of Credit and such registration statement became effective. In exchange for the Equity Line of Credit, the Company is obligated to issue Helena a certain number of shares of common stock, calculated using $900 divided by the lowest one-day VWAP during the five trading days prior to entry into the agreement. As a result, the Company issued Helena <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20241112__20241112__dei--LegalEntityAxis__custom--HelenaGlobalInvestmentOpportunitiesILTDMember_zDLO2zdWllc" title="Number of shares issued">670,641 shares of its common stock valued at $1,377 on the date of issuance. The Company accounted for the value of the shares issued as deferred offering costs. The shares vested on the date of the agreement, were issued to Helena, and were subject to a “true up” based upon the value of the stock after the company filed and obtained effectiveness of the registration statement registering the ELOC shares for resale. At December 31, 2024, the balance of the deferred offering costs was $1,377. On April 24, 2025, the Company issued another <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250424__20250424__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--HelenaGlobalInvestmentOpportunitiesILTDMember_zUZFITPC85H5" title="Number of shares issued">384,459 shares of its common stock to Helena. The fair value of the shares on the date of grant was $<span id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn3n3_c20250424__20250424__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--HelenaGlobalInvestmentOpportunitiesILTDMember_zQh0trn36Rrj" title="Number of shares issued, value">328. The Company recorded the fair value of the shares as deferred offering costs as of the same date. During the year ended December 31, 2025, the Company amortized $614 of these costs as shares were issued under the agreement. As of December 31, 2025, the balance of the deferred offering costs was $1,091.

30000000

900000

670641

1377000

384459

328000

614000

1091000

NOTE 5 – SHAREHOLDERS’ EQUITY Common Stock Authorized Shares The Company’s Certificate of Incorporation, as filed with the State of Delaware on May 10, 2023, following the Company’s conversion from a California corporation into a Delaware corporation, authorizes the Company to issue up to 120,000,000 shares, consisting of 100,000,000 shares of common stock, par value of $0.001 per share, and 20,000,000 shares of preferred stock, par value $0.001 per share. Holders of shares of common stock have full voting rights, one vote for each share held of record. Shareholders are entitled to receive dividends as may be declared by the board of directors out of funds legally available and share pro rata in any distributions with shareholders upon liquidation. Shareholders have no conversion, pre-emptive or subscription rights. All outstanding shares of common stock are fully paid and non-assessable. As of December 31, 2025 and 2024, there were 20,821,353 and 13,736,597 shares of common stock issued and outstanding, respectively, and no shares of preferred stock outstanding, respectively. Common Stock Issued for Cash Upon Closing of the Company’s IPO On September 17, 2024, the Company completed the IPO of its common stock in which the Company issued and sold 1,550,000 shares of its common stock at a public offering price of $4.00 per share. The total gross proceeds of the IPO were $<span id="xdx_90E_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pn3n3_c20240916__20240916__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_z6cETR2tyad" title="Gross proceeds proceeds from issuance initial public offering">6,200 and the Company raised $<span id="xdx_903_ecustom--NetProceedsFromIssuanceInitialPublicOffering_pn3n3_c20240917__20240917__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zMe0qRDo9nC6" title="Net proceeds proceeds from issuance initial public offering">5,524 in net proceeds after deducting underwriting discounts and commissions and offering expenses payable by the Company, excluding deferred offering costs of $<span id="xdx_903_ecustom--ReclassificationOfDeferredOfferingCostsToShareholdersEquity_pn3n3_c20250101__20251231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zkJcTRqsy8Ta" title="Reclassification of deferred offering costs to shareholders equity">872. The underwriters were granted a 45-day option to purchase up to an additional 232,500 shares of common stock from the Company. No additional shares were sold under the 45-day option. On September 17, 2024, pursuant to the underwriting agreement, the Company issued common stock purchase warrants to the underwriters to purchase up to <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240917__20240917__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--TypeOfArrangementAxis__custom--UnderwrintingAgreementMember_zmrKeRbofWM6" title="Shares issued">108,500 shares of the Company’s common stock, at an exercise price of $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240917__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--TypeOfArrangementAxis__custom--UnderwrintingAgreementMember_z7zbrFbvzUlb" title="IPO price">4.80 per share, subject to adjustments. The warrants will be exercisable during the period commencing on March 16, 2025 and ending on September 17, 2029, and may be exercised on a cashless basis under certain circumstances. Common Stock Issued Upon Conversion of Convertible Notes Payable and Accrued Interest During the year ended December 31, 2022, the Company entered into several convertible note payable agreements with certain investors totaling $675, with adjustments increasing the principal balance to $792 as of September 17, 2024, the date of the Company’s IPO. Upon closing of the Company’s IPO, the principal amount of $792, plus the accrued and unpaid interest of $92, totaling $<span id="xdx_902_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_pn3n3_c20250101__20251231__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_zn4SEr3ivLji" title="Issuance of common shares upon conversion of convertible notes payable and accrued interest">884, automatically converted into <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20240917__20240917__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_znl1tY3nf5L7" title="Issuance of common shares upon conversion of convertible notes payable and accrued interest, shares">368,371 shares of the Company’s common stock based on the principal and accrued interest due as of September 17, 2024. Common Stock Issued Upon Conversion of Accounts Payable During the year ended December 31, 2024, the Company entered into an agreement with Cedars-Sinai Medical Center (“Cedars”) under which Cedars agreed to convert $<span id="xdx_907_eus-gaap--ConversionOfStockAmountIssued1_pn3n3_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--CedarsSinaiMedicalCenterMember_z9Y3DBkqRLdb" title="Conversion of accounts payable">750 of the total accounts payable due to them into 312,500 shares of the Company’s common stock, with such conversion to occur upon the closing of the Company’s IPO. The conversion price of the shares was equal to <span id="xdx_907_ecustom--ConversionPricePercentage_pid_dp_uPure_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--CedarsSinaiMedicalCenterMember_zXD1cPEWj4Uc" title="Conversion price per share percentage">60% of the per share IPO price, or $2.40 per share. Upon the closing of the IPO, the shares were issued to Cedars and the debt was forgiven. The fair value of the shares was $1,250. The Company recorded the difference between the fair value of the shares and the debt forgiven as a financing cost of $500, which was recorded during the year ended December 31, 2024. Also, during the year ended December 31, 2024, the Company entered into another agreement with Cedars under which Cedars agreed to convert $<span id="xdx_90A_eus-gaap--ConversionOfStockAmountIssued1_pn3n3_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--AnotherCedarsSinaiMedicalCenterMember_zG6Iejn5E2G8" title="Conversion of accounts payable">200 of the total accounts payable due to them into 150,830 shares of the Company’s common stock. The conversion price of the shares was equal to <span id="xdx_905_ecustom--ConversionPricePercentage_pid_dp_uPure_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--AnotherCedarsSinaiMedicalCenterMember_zhm5013PFiL2" title="Conversion price per share percentage">60% of the closing price of the Company’s common stock on the date of the agreement, or $1.33 per share. The fair value of the shares was $333. The Company recorded the difference between the fair value of the shares and the debt forgiven as a financing cost of $133, which was recorded during the year ended December 31, 2024. During the year ended December 31, 2024, the Company entered into an agreement with its Chief Financial Officer (“CFO”), under which he agreed to convert $172 of the total accounts payable due to him into 51,610 shares of the Company’s common stock with such conversion to occur upon the closing of the Company’s IPO. The conversion price of the shares was equal to <span id="xdx_906_ecustom--ConversionPricePercentage_pid_dp_uPure_c20240101__20241231__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_zcaQv61yHix4" title="Conversion price per share percentage">83% of the IPO price. Upon the closing of the IPO, the shares were issued to the CFO. The fair value of the shares was $206. The Company recorded the difference between the fair value of the shares and the accounts payable forgiven as a financing cost of $34, which was recorded during the year ended December 31, 2024. No amounts were owed to the CFO as of December 31, 2024. In summary, during the year ended December 31, 2024, the company issued 514,940 shares of its common stock with a fair value of $1,789 relating to the conversion of its account payable. Common Stock Issued Upon Conversion of Amounts Due to Related Parties During the year ended December 31, 2021, shareholders of the Company, and a company whose principal stockholder is also a stockholder of the Company, advanced the Company $14. As of September 17, 2024, the date of the closing of the Company’s IPO, a total of $4 was outstanding. During the year ended December 31, 2024, the officers agreed to automatically convert the principal into shares of the Company’s common stock upon the closing of the IPO transaction. Upon the closing of the IPO, all of the principal automatically converted into 1,664 shares of the Company’s common stock based on the conversion price of $<span id="xdx_90F_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--SixtyPercentageOfIPOClosingPriceMember_zVyecdz4Kezh">2.40, which was 60% of the IPO closing price of $4. As the officers received 666 additional shares based on the 40% discounted price, the fair value of those shares, $3, was recorded as a financing cost during the year ended December 31, 2024. As of December 31, 2024, no principal or interest was due on the advances. Common Stock Issued for Advances to Vendors On October 1, 2024, the Company entered into a consulting agreement (the “Consulting Agreement”) with Cross Current Capital LLC, a limited liability company organized under the laws of Puerto Rico (“Cross Current”), and Alan Masley (the “Advisor”), pursuant to which Cross Current agreed to provide certain financial and business consulting services to the Company. For the services rendered thereunder, the Company agreed to issue to the Advisor $<span id="xdx_909_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn3n3_c20241001__20241001__us-gaap--TypeOfArrangementAxis__custom--CrossCurrentCapitalLLCMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zrGpUWs8NDM6" title="Stock issued value">500 of restricted shares of the Company’s common stock under the Company’s 2023 Plan, which was calculated at <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20241001__20241001__us-gaap--TypeOfArrangementAxis__custom--CrossCurrentCapitalLLCMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_znhM49oJMTyk" title="Stock issued shares">367,647 shares (the “Shares”) as of the date of the agreement. The Shares were subsequently issued to Cross Current in 2025. The value of the shares issued of $500 are included in Vendor Advances on the accompanying Balance Sheet as of December 31, 2025 and 2024 (see Note 3). The Shares were subject to a “true up” on April 1, 2025, at which time additional shares were either issuable to the Advisor or to be returned by the Advisor to the Company in order to ensure the shares were valued at $<span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn3n3_c20250401__20250401__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_znqMzfiSxebj" title="Number of shares issued, value">500 as of April 1, 2025. Accordingly, on April 1, 2025, the Company issued an additional <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250401__20250401__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zNplJkO3fP4a" title="Number of shares issued">166,541 shares of its common stock to the Advisor to bring the value to $<span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn3n3_c20250401__20250401__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zcYVRU0g8EK8" title="Number of shares issued, value">500. The fair value of the additional shares on the date of grant was $<span id="xdx_909_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn3n3_c20250401__20250401__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zy9EbDJaqUB3" title="Number of shares issued, value">157. The Company recorded the fair value of the shares as a Vendor Advance as of the same date (see Note 3). Common Stock Issued for Cash Upon Closing of the Company’s Private Financing On January 14, 2025, the Company entered into a securities purchase agreement (“SPA”) and registration rights agreement with an investor for the sale and issuance of <span id="xdx_909_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20250114__20250114__us-gaap--SubsidiarySaleOfStockAxis__custom--SecurityPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantMember_zebtdwjhE1jd" title="Sale of stock, number of shares issued in transaction">2,500,000 units (the “Pre-Funded Units”), with each Pre-Funded Unit consisting of a pre-funded warrant to purchase one share of common stock, exercisable for $<span id="xdx_905_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20250114__us-gaap--SubsidiarySaleOfStockAxis__custom--SecurityPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantMember_zXsLhEG38I6d" title="Exercisable price per share">0.001 per share, and a common warrant to purchase one and one half shares of common stock (an aggregate of <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pp0p0_c20250114__us-gaap--SubsidiarySaleOfStockAxis__custom--SecurityPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantMember_zlYkp1mfRRCk" title="Warrants to purchase of common stock">3,750,000), exercisable at $<span id="xdx_90A_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20250114__us-gaap--SubsidiarySaleOfStockAxis__custom--SecurityPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zo4hM9XZlLb3" title="Exercisable price per share">1.399 per share. On January 16, 2025, the Company closed on the sale of the Pre-Funded Units for a total purchase price of $<span id="xdx_902_eus-gaap--SaleOfStockConsiderationReceivedPerTransaction_pn3n3_c20250116__20250116__us-gaap--SubsidiarySaleOfStockAxis__custom--SecurityPurchaseAgreementMember_z3Wg4qWJvpm5" title="Purchase price of pre-funded unit">3,500 (or $1.40 per Pre-Funded Unit). Net proceeds received by the Company relating to the financing, and subsequent exercise of prefunded warrants was $<span id="xdx_904_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn3n3_c20250116__20250116__us-gaap--SubsidiarySaleOfStockAxis__custom--SecurityPurchaseAgreementMember_zgwneomQ6pA1" title="Net proceeds received from financing">3,058. The pre-funded warrants have an exercise price of $<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250114__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zUqE8WWkdUoc" title="Exercise price">0.001 per share and are immediately exercisable and will expire when exercised in full. The common warrants have an exercise price of $1.40 per share, will be exercisable six months from issuance and will expire five and a half years from the issuance date. During the year ended December 31, 2025, the investor exercised <span id="xdx_90C_ecustom--StockIssuedDuringPeriodSharesIssuanceOfCommonSharesUponExerciseOfPrefundedWarrants_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zzbEjlXlait8" title="Warrants exercised">2,500,000 shares of the pre-funded warrants and as of December 31, 2025, there were no pre-funded shares remaining unexercised. Common Stock Issued for Cash Upon Exercise of the Company’s Equity Line of Credit (ELOC) During the year ended December 31, 2025, in connection with its ELOC agreement with Helena, the Company sold <span id="xdx_90A_ecustom--StockIssuedDuringPeriodSharesCommonSharesIssuedForCashThroughEquityLineOfCredit_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zYHSHHzkwJG3" title="Common stock issued for cash upon exercise of the company's equity line of credit, shares">3,510,000 shares of its common stock to Helena for net proceeds of $2,988, which includes the allocation of deferred offering costs of $614. The shares were issued to Helena during the year ended December 31, 2025. Adoption of the 2023 Equity Incentive Plan In July 2023, the Company’s board of directors and stockholders adopted the 2023 Equity Incentive Plan (the “2023 Plan”). Under the 2023 Plan, the Company may grant incentive stock options to employees, including employees of any parent or subsidiary, and nonstatutory stock options, stock appreciation rights, restricted stock awards, RSU awards, performance awards and other forms of stock compensation to employees, directors and consultants, including employees and consultants of the Company’s affiliates. As approved, a total of <span id="xdx_909_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20230731__us-gaap--PlanNameAxis__custom--TwentyTwentyThreeEquityIncentivePlanMember_zGdz2WgUItQ9" title="Common stock reserved for future issuance">1,650,000 shares of common stock were initially reserved for issuance under the 2023 Plan. As of December 31, 2025, and 2024, a total of <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20251231__us-gaap--PlanNameAxis__custom--TwentyTwentyThreeEquityIncentivePlanMember_zMz7IfRdzJ6l" title="Shares available for grant">877,395 shares and <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--TwentyTwentyThreeEquityIncentivePlanMember_zVizTTqIblpe" title="Shares available for grant">1,478,000 remained available for issuance under the 2023 Plan, respectively. Grant of Restricted Stock Units (RSUs) <p id="xdx_890_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_zMayEkIqJv9f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The following table summarizes restricted common stock activity during the years ended December 31, 2024 and 2025: SCHEDULE OF RESTRICTED COMMON STOCK ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number of Restricted Shares</td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Grant Date Fair Value</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Unvested, December 31, 2023</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zdbuxdolRnFa" style="text-align: right" title="Number of Restricted Shares, Unvested Beginning balance">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pn3n3_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zIk7XdYRglpl" style="text-align: right" title="Fair Value, Unvested, Beginning balance">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zvBGHxahWw19" style="text-align: right" title="Weighted Average Grant Date Fair Value, Beginning balance">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 46%; text-align: justify">Granted</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zquNd1D4s9il" style="width: 14%; text-align: right" title="Number of Restricted shares Granted">240,341</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_980_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedInPeriodFairValue1_pn3n3_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zjQ9ng6cIf43" style="width: 14%; text-align: right" title="Fair Value, Granted">532</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zctgSPDcCird" style="width: 14%; text-align: right" title="Weighted Average Grant Date Fair Value, Granted">2.21</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Vested</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_iN_pid_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z5gZ9TIqMJQc" style="text-align: right" title="Number of Restricted shares Vested">(68,341</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_iN_pn3n3_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z5DocBDnpWz2" style="text-align: right" title="Fair Value, Vested">(218</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z8NRqRvtHbEg" style="text-align: right" title="Weighted Average Grant Date Fair Value, Vested">3.19</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; text-align: justify">Forfeited</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zIG5mzo53Z84" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Restricted shares Forfeited">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedInPeriodFairValue1_pn3n3_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zc3KdkrQr389" style="border-bottom: Black 1pt solid; text-align: right" title="Fair Value, Forfeited">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zxSVTdAG8dlh" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Grant Date Fair Value, Forfeited">—</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Unvested, December 31, 2024</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zuDhSHkgud4l" style="text-align: right" title="Number of Restricted Shares, Unvested Beginning balance">172,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z3J71Dg7ONp3" style="text-align: right" title="Fair Value, Unvested, Beginning balance">314</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zotk75VMSrX2" style="text-align: right" title="Weighted Average Grant Date Fair Value, Beginning balance">1.83</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zFFYjZl4nvbe" style="text-align: right" title="Number of Restricted shares Granted">745,312</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedInPeriodFairValue1_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zaaqnB6k0jmd" style="text-align: right" title="Fair Value, Granted">981</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zpD2vzFd0ZFa" style="text-align: right" title="Weighted Average Grant Date Fair Value, Granted">1.32</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Vested</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_iN_pid_di_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zNIEiC241yI" style="text-align: right" title="Number of Restricted shares Vested">(144,707</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_iN_pn3n3_di_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zNuzOWfYkA5a" style="text-align: right" title="Fair Value, Vested">(482</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zHNK7xWX3Ze5" style="text-align: right" title="Weighted Average Grant Date Fair Value, Vested">3.33</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; text-align: justify">Forfeited</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zCBz0FuVUiG8" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Restricted shares Forfeited">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedInPeriodFairValue1_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zLqtYEdOMD6a" style="border-bottom: Black 1pt solid; text-align: right" title="Fair Value, Forfeited">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zBkvNNmmcWK6" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Grant Date Fair Value, Forfeited">—</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; text-align: justify">Unvested, December 31, 2025</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zGBLwXoNm9Qc" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Restricted Shares, Unvested Ending balance">772,605</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zcfiYA0O34jk" style="border-bottom: Black 1pt solid; text-align: right" title="Fair Value, Unvested, Ending balance">813</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zNSTOXJZ42Mi" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Grant Date Fair Value, Ending balance">1.05</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table> On October 8, 2025, the Company’s Compensation Committee of the board of directors approved the grant of an aggregate total of <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20251008__20251008__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_zOBA2ljZ5Htd" title="Aggregate stock granted">667,940 RSUs to the Company’s executive officers and directors for their services to be performed from October 2025 to October 2026. The RSUs were granted under the Company’s 2023 Equity Incentive Plan and were valued at $<span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_pn3n3_c20251008__20251008__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeEquityIncentivePlanMember_z0o48WgeRvi6" title="Aggregate stock granted value">875 on the date of grant. Additionally, the Company’s independent directors received an aggregate total of <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pid_c20251008__20251008__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_zeHuVWBwoBB5" title="Aggregate restricted stock unit">57,252 RSUs, with a value of $<span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_pn3n3_c20251008__20251008__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_zKS1GhC8bFoh" title="Aggregate restricted stock unit value">75 on the date of grant. Each RSU represents the right to receive one share of the Company’s common stock upon vesting. The RSUs will vest in full on October 8, 2026, the first anniversary following the grant date, subject to the recipient’s continuous service with the Company through such vesting date. Notwithstanding the foregoing vesting schedule, in the event of a change in control of the Company (as defined in the Plan) occurring prior to the vesting date, all unvested RSUs will become fully vested immediately upon the occurrence of such change in control. On September 23, 2024, the Company entered into a strategic advisory agreement with Belair Capital Advisors Inc. (“Belair”). During the one-year term of the agreement, in exchange for its services, the Company issued Belair <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240923__20240923__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--TypeOfArrangementAxis__custom--StrategicAdvisoryAgreementMember_zzototYiWgMl" title="Number of shares issued">50,000 RSUs, which vest nine months from the date of issuance. The fair value of the shares on the date of grant was $<span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_pn3n3_c20240923__20240923__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--TypeOfArrangementAxis__custom--StrategicAdvisoryAgreementMember_zB3QtQmlQ81d" title="Fair value of shares">100, which value will be amortized over the one-year service period of the agreement. <span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_dn_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--StrategicAdvisoryAgreementMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zrVEoRwndlse" title="Number of shares vested">None of these shares vested or were issued during the year ended December 31, 2024. During the years ended December 31, 2025, the <span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--TypeOfArrangementAxis__custom--StrategicAdvisoryAgreementMember_zS4BpuuovUbj" title="Number of shares vested">50,000 RSUs vested and the shares were issued to Belair. As of December 31, 2025, <span id="xdx_90D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedNumberOfShares_pid_do_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--TypeOfArrangementAxis__custom--StrategicAdvisoryAgreementMember_zjgtgo0fz7qj" title="Number of shares unvested">no RSUs remained unvested. Upon the closing of the Company’s IPO, the Company entered into agreements with each of its four officers. Such agreements provided for annual grants of RSUs in accordance with the terms of the Company’s 2023 Equity Incentive Plan. The RSUs vest over one- or two-year periods and are subject to full acceleration of vesting upon the sale of the Company. Upon the closing of the Company’s IPO in September 2024, the Company granted the officers <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240901__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--TypeOfArrangementAxis__custom--FourOfficersAgreementMember_ze1la38KGNjc" title="Number of shares issued">92,000 RSUs. The fair value of the shares on the date of grant was $<span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_pn3n3_c20240901__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--TypeOfArrangementAxis__custom--FourOfficersAgreementMember_zwrj9iSj4ln8" title="Fair value of shares">226. <span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_dn_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--FourOfficersAgreementMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zg9KPWKU6bzg" title="Number of shares vested">None of these RSUs vested during the year ended December 31, 2024. During the years ended December 31, 2025, a total of <span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pid_c20250101__20251231__us-gaap--TypeOfArrangementAxis__custom--FourOfficersAgreementMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z5UcJTOfMqfc" title="Number of shares vested">78,000 RSUs vested, and the shares were issued to the officers. As of December 31, 2025, <span id="xdx_905_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedNumberOfShares_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--TypeOfArrangementAxis__custom--FourOfficersAgreementMember_zVM1lRxDhMmb" title="Number of shares unvested">14,000 RSUs remained unvested. Upon the closing of the Company’s IPO, the Company entered into agreements with each of its three independent directors. The Company’s policy provides that, upon initial election or appointment to its board of directors, each new non-employee director will be granted a one-time grant, or Director Initial Grant, that will vest in substantially equal annual installments over a period of three years. The Director Initial Grant is subject to full acceleration of vesting upon the sale of the Company, in accordance with the terms of the Company’s 2023 Plan. In 2024, a total of <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zOmq4IqZXRa7" title="Number of shares granted">30,000 RSUs were granted to the directors. The fair value of the RSUs on the date of grant was $<span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_pn3n3_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zZ2LzCKbztq2" title="Fair value of shares">43. None of the RSUs vested during the year ended December 31, 2024. During the years ended December 31, 2025, an additional <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zXjEczbImBt7" title="Number of shares granted">20,120 RSUs were granted to the Company’s new director with a fair value of $<span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__srt--DirectorMember_z41uH53XJiOf" title="Fair value of shares">31. During the year ended December 31, 2025, a total of <span id="xdx_905_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsVestedNumberOfShares_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zaZN2hoRO7T9" title="Number of shares vested">16,707 shares vested, and <span id="xdx_901_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedNumberOfShares_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z4W2woQkVO5d" title="Number of shares unvested">33,413 RSUs remained unvested. During the years ended December 31, 2025, the Company recorded $<span id="xdx_90C_ecustom--FairValueOfRestrictedStockUnits_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z2ERiV0J93N3" title="Stock compensation-related expense for fair value vesting of restricted common stock">482 of stock compensation-related expense for the fair value vesting of restricted common stock. As of December 31, 2025, $813 of unamortized compensation remained. Stock Warrants The table below summarizes the Company’s warrant activities for years ended December 31, 2024 and 2025: SCHEDULE OF WARRANT ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number of Warrant Shares</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Exercise Price Range Per Share</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%; text-align: justify">Balance, December 31, 2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z0DqfreooQb1" style="width: 14%; text-align: right" title="Warrants Shares, Beginning Balance">150,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><span id="xdx_909_ecustom--ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfOutstandingWarrants_iS_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zsL54D8Bvr3i" title="Exercise Price Range Per Share, Beginning">4.17</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zGd08164eOD2" style="width: 14%; text-align: right" title="Weighted Average Exercise Price Warrant Warrant, Beginning Balance">4.17</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zUxb22iM2l37" style="text-align: right" title="Warrants Shares, Granted">128,188</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_902_ecustom--ShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeGranted_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zwYL8BdhZW0i" title="Exercise Price Range Per Share, Granted">2.40 – <span id="xdx_90B_ecustom--ShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeGranted_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zARetgLlVnB1" title="Exercise Price Range Per Share, Granted">4.80 </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zr9kYpcRvjoh" style="text-align: right" title="Weighted Average Exercise Price Warrant, Granted">4.43</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Cancelled</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zIIq02CDmxX1" style="text-align: right" title="Warrants Shares, Cancelled">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_ecustom--ShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeCancelled_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zR4xOpCE9nub" style="text-align: right" title="Exercise Price Range Per Share, Cancelled">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledWeightedAverageGrantDateFairValue_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zOmOWgQ0yCb3" style="text-align: right" title="Weighted Average Exercise Price Warrant, Cancelled">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_iN_pid_di_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zI2JaOm1N6K4" style="text-align: right" title="Warrants Shares, Exercised">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_909_ecustom--ShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeExercised_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zvz9oBXRdUw3" title="Exercise Price Range Per Share, Exercised">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zsoIoRyS3zE2" style="text-align: right" title="Weighted Average Exercise Price Warrant, Exercised">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; text-align: justify">Forfeited/Expired</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zxq7PUwd532e" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants Shares, Forfeited/Expired">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_ecustom--ShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeForfeited_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z4y9tQE2kbGf" style="border-bottom: Black 1pt solid; text-align: right" title="Exercise Price Range Per Share, Forfeited/Expired">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zykypXb10V7c" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Warrant, Forfeited/Expired">—</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Balance, December 31, 2024</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z609btH9mtsl" style="text-align: right" title="Warrants Shares, Beginning Balance">278,188</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_ecustom--ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfOutstandingWarrants_iS_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_z6N6WJ21jJ61" title="Exercise Price Range Per Share, Beginning">2.40 - <span id="xdx_907_ecustom--ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfOutstandingWarrants_iS_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zG5EqQzVenq7" title="Exercise Price Range Per Share, Beginning">4.80</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z32TMMMegF5k" style="text-align: right" title="Weighted Average Exercise Price Warrant Warrant, Beginning Balance">4.29</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zTZhXbf4Ed0i" style="text-align: right" title="Warrants Shares, Granted">6,670,700</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_ecustom--ShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeGranted_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zXhPOxB3pz45" title="Exercise Price Range Per Share, Granted">0.001 – <span id="xdx_90D_ecustom--ShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeGranted_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zdAW0ynhcsP2" title="Exercise Price Range Per Share, Granted">1.40</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zCeHIw2z793l" style="text-align: right" title="Weighted Average Exercise Price Warrant, Granted">0.87</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Cancelled</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zWM6XhJ7OMF" style="text-align: right" title="Warrants Shares, Cancelled">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--ShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeCancelled_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zRyTk4amyyHk" style="text-align: right" title="Exercise Price Range Per Share, Cancelled">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledWeightedAverageGrantDateFairValue_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_znGGu0gUEaXa" style="text-align: right" title="Weighted Average Exercise Price Warrant, Cancelled">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_iN_pid_di_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zNSBY6GaMROf" style="text-align: right" title="Warrants Shares, Exercised">(2,517,850</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_ecustom--ShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeExercised_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zfczOJZ14VZ1" title="Exercise Price Range Per Share, Exercised">0.001 – <span id="xdx_90D_ecustom--ShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeExercised_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_z5xgcuAL2Rrl" title="Exercise Price Range Per Share, Exercised">0.46</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zWpB3QROoGG3" style="text-align: right" title="Weighted Average Exercise Price Warrant, Exercised">0.004</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; text-align: justify">Forfeited/Expired</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zpTfRb2RuaNj" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants Shares, Forfeited/Expired">(150,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98E_ecustom--ShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeForfeited_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zw3DWutzwhAk" style="border-bottom: Black 1pt solid; text-align: right" title="Exercise Price Range Per Share, Forfeited/Expired">4.17</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zGSrX6pUcMqi" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Warrant, Forfeited/Expired">4.17</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; text-align: justify">Balance, December 31, 2025</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zbXlgNEU8Iza" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants Shares, Ending Balance">4,281,038</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90B_ecustom--ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfOutstandingWarrants_iE_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zWPM6AVFmnI6" title="Exercise Price Range Per Share, Ending">0.40 – <span id="xdx_90D_ecustom--ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfOutstandingWarrants_iE_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zVchvum777U6" title="Exercise Price Range Per Share, Ending">4.80</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zZcdcnGcjwQa" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Warrant, Ending Balance">1.48</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; text-align: justify">Vested and exercisable, December 31, 2025</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExcercisableInPeriod_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zaVf8hAsVbR4" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Shares Warrants, Vested and exercisable">4,281,038</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_904_ecustom--ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfVestedAndExercisable_iE_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zX0w6vleEBbj" title="Exercise Price Range Per Share, Vested and exercisable">0.40 – <span id="xdx_906_ecustom--ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfVestedAndExercisable_iE_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zdcU4KDryve3" title="Exercise Price Range Per Share, Vested and exercisable">4.80</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ztXj27qgOX5c" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Vested and exercisable">1.48</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table> The following table summarizes information concerning outstanding and exercisable warrants as of December 31, 2025: SCHEDULE OF OUTSTANDING AND EXERCISABLE WARRANTS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td colspan="2" style="text-align: right"> </td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants Outstanding</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants Exercisable</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Range of Exercise Prices</td><td style="text-align: center; padding-bottom: 1pt"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number Outstanding</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Average Remaining Contractual Life (in years)</td><td style="text-align: center; padding-bottom: 1pt"> </td><td style="text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Exercise Price</td><td style="text-align: center; padding-bottom: 1pt"> </td><td style="text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number Exercisable</td><td style="text-align: center; padding-bottom: 1pt"> </td><td style="text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Average Remaining Contractual Life (in years)</td><td style="text-align: center; padding-bottom: 1pt"> </td><td style="text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Exercise Price</td><td style="text-align: center; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><span id="xdx_90E_ecustom--ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfOutstandingWarrants_iI_pid_c20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantOneMember__srt--RangeAxis__srt--MinimumMember_zo4LIBEEs2z1" title="Range of exercise prices">0.40 - <span id="xdx_908_ecustom--ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfOutstandingWarrants_iI_pid_c20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantOneMember__srt--RangeAxis__srt--MaximumMember_zK9FnQ5vsDWe" title="Range of exercise prices">0.46</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantOneMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zso0q2CIVr4k" title="Warrants Outstanding, Number Outstanding">17,850</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantOneMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zyjiHVTSRY3l" title="Warrants Outstanding, Average Remaining Contractual Life (in years)">4.42</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantOneMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_znhUpyXVIb4" title="Warrants Outstanding, Weighted Average Exercise Price">0.46</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right"><span id="xdx_902_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExercisableNumber_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantOneMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zaQQgMosWdDg" title="Warrants Exercisable, Number Exercisable">17,850</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right"><span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms_dtY_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantOneMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zLdgiZaDZtl7" title="Warrants Exercisable, Average Remaining Contractual Life (in years)">4.42</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><span id="xdx_90A_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePrice_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantOneMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_znORXNtna755" title="Warrants Exercisable, Weighted Average Exercise Price">0.46</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_ecustom--ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfOutstandingWarrants_iI_pid_c20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantTwoMember__srt--RangeAxis__srt--MinimumMember_zpnGDZXewoHd" title="Range of exercise prices">1.23 - <span id="xdx_902_ecustom--ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfOutstandingWarrants_iI_pid_c20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantTwoMember__srt--RangeAxis__srt--MaximumMember_zKCLVu3Xp7u5" title="Range of exercise prices">2.40</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantTwoMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zJdDq72rWe65" title="Warrants Outstanding, Number Outstanding">4,154,688</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantTwoMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zoYBbcQguLg3" title="Warrants Outstanding, Average Remaining Contractual Life (in years)">4.02</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantTwoMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_z1S3Vfmn6Ocb" title="Warrants Outstanding, Weighted Average Exercise Price">1.40</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExercisableNumber_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantTwoMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zpXz6anLNbhf" title="Warrants Exercisable, Number Exercisable">4,154,688</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms_dtY_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantTwoMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zWMg2UJQ7HIl" title="Warrants Exercisable, Average Remaining Contractual Life (in years)">4.02</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90D_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePrice_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantTwoMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zYvf0arxqwDb" title="Warrants Exercisable, Weighted Average Exercise Price">1.40</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_909_ecustom--ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfOutstandingWarrants_iI_pid_c20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantThreeMember_zl9lEXYNkfLc" title="Range of exercise prices">4.80</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantThreeMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_zf5LqrQC21W1" title="Warrants Outstanding, Number Outstanding">108,500</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantThreeMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_z6plfu5Ir819" title="Warrants Outstanding, Average Remaining Contractual Life (in years)">3.75</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantThreeMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_zF0Bkv5Qr5vf" title="Warrants Outstanding, Weighted Average Exercise Price">4.80</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_900_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExercisableNumber_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantThreeMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_zTyX2DWA7CJj" title="Warrants Exercisable, Number Exercisable">108,500</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms_dtY_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantThreeMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_zRZdISELzto9" title="Warrants Exercisable, Average Remaining Contractual Life (in years)">3.75</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90A_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePrice_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantThreeMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_zDkHm5TKlsu2" title="Warrants Exercisable, Weighted Average Exercise Price">4.80</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_ecustom--ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfOutstandingWarrants_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zYFYzjuvWeWf" title="Range of exercise prices">0.40 - <span id="xdx_90F_ecustom--ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfOutstandingWarrants_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zr6mT1uL7aid" title="Range of exercise prices">4.80</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z1HmJNNK4b5" title="Warrants Outstanding, Number Outstanding">4,281,038</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zrWLZu9Ioeuc" title="Warrants Outstanding, Average Remaining Contractual Life (in years)">4.01</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zFlYa7kgHnlg" title="Warrants Outstanding, Weighted Average Exercise Price">1.48</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExercisableNumber_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z7i4etFKGDgh" title="Warrants Exercisable, Number Exercisable">4,281,038</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms_dtY_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z7yUcCzxslQ8" title="Warrants Exercisable, Average Remaining Contractual Life (in years)">4.01</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePrice_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zHMCWjTyAy8c" title="Warrants Exercisable, Weighted Average Exercise Price">1.48</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Warrant Grants On January 14, 2025, as amended on January 16, 2025, the Company entered into a securities purchase agreement (“SPA”) and registration rights agreement with a select investor. In connection with the agreement, on January 16, 2025, the Company issued the investor a pre-funded warrant to purchase up to <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20250116__us-gaap--SubsidiarySaleOfStockAxis__custom--SecurityPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_z9dH3amJDTLc" title="Warants to purchase of common stock">2,500,000 shares of the Company’s common stock at an exercise price of $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250116__us-gaap--SubsidiarySaleOfStockAxis__custom--SecurityPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zI7qgWuls1yh" title="Exercisable price per share">0.001 per share. The warrant is immediately exercisable and will expire when exercised in full. During the years ended December 31, 2025, the SPA investor exercised <span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20251231__us-gaap--SubsidiarySaleOfStockAxis__custom--SecurityPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zXypUmgoe2Jk" title="Warants to purchase of common stock">2,500,000 shares of the pre-funded warrant, and as of December 31, 2025, there were no shares remaining unexercised. The investor also received a warrant to purchase up to <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20251231__us-gaap--SubsidiarySaleOfStockAxis__custom--SecurityPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zaC8HYVB4Dk8" title="Warrants to purchase of common stock">3,750,000 shares of the Company’s common stock at an exercise price of $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20251231__us-gaap--SubsidiarySaleOfStockAxis__custom--SecurityPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zSFS94ynqOlc" title="Exercisable price per share">1.40 per share. <span id="xdx_90A_ecustom--ClassOfWarrantOrRightsDateFromWhichWarrantsOrRightsExercisableDescription_c20250101__20251231__us-gaap--SubsidiarySaleOfStockAxis__custom--SecurityPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zQz2en4pwL7" title="Warrants exercisable description">The warrant will be exercisable six months from the date of issuance (July 2025) and will expire five years from the issuance date. All the warrant shares were exercisable as of December 31, 2025. On January 16, 2025, the Company issued a warrant to purchase common stock to the underwriters of the SPA for the purchase of <span id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20250116__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zSFEZJXfLcG1" title="Warrants to purchase stock">175,000 shares of the Company’s common stock at an exercise price of $<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250116__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z4HuBks0vKd5" title="Exercisable price per share">1.40 per share. The warrant vested upon grant. The warrant was issued to the underwriters as they were the placement agents for the SPA noted above. <span id="xdx_906_ecustom--ClassOfWarrantOrRightsDateFromWhichWarrantsOrRightsExercisableDescription_c20250116__20250116__us-gaap--SubsidiarySaleOfStockAxis__custom--SecurityPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--UnderwritersMember_zvbi53nCCER5" title="Warrants exercisable description">The warrant expires five years from the date of grant. In May and June 2025, the Company issued warrants to purchase common stock to the underwriters of the SPA for the purchase of <span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20250531__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zzoczYufOB5g" title="Warrants to purchase stock"><span id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zPOBcdOl1eGg" title="Warrants to purchase stock">35,700 shares of the Company’s common stock at exercise prices of $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250531__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zB63l7JffCCg" title="Exercisable price per share">0.40 and $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zdyojmpRDTHc" title="Exercisable price per share">0.46 per share. The warrants vested upon grant. The warrants were issued to the underwriters as they were the placement agents for the SPA noted above. <span id="xdx_90A_ecustom--ClassOfWarrantOrRightsDateFromWhichWarrantsOrRightsExercisableDescription_c20250501__20250531__us-gaap--SubsidiarySaleOfStockAxis__custom--SecurityPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--UnderwritersMember_zWL6gvpXTGn2" title="Warrants exercisable description"><span id="xdx_90F_ecustom--ClassOfWarrantOrRightsDateFromWhichWarrantsOrRightsExercisableDescription_c20250601__20250630__us-gaap--SubsidiarySaleOfStockAxis__custom--SecurityPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--UnderwritersMember_zBVy1sFCLi28" title="Warrants exercisable description">The warrants expire five years from the date of grant. During the year ended December 31, 2025, a total of <span id="xdx_900_ecustom--StockIssuedDuringPeriodSharesCashlessStockWarrantsExercised_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--TypeOfArrangementAxis__custom--SecurityPurchaseAgreementMember_zb8RnlRlUomk" title="Common stock were issued under the cashless exercise">17,850 shares were exercised under a cashless exercise, leaving <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--TypeOfArrangementAxis__custom--SecurityPurchaseAgreementMember_zKuoqjKPOmS1" title="Warrant exercisable and outstanding">17,850 shares outstanding and exercisable. A total of <span id="xdx_905_ecustom--StockIssuedDuringPeriodSharesCashlessStockWarrantsExercised_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zagcXM3Crndj" title="Common stock were issued under the cashless exercise">11,402 shares of the Company’s common stock were issued pursuant to cashless exercise. In July 2025, the Company issued warrants to purchase common stock to the underwriters of the SPA for the purchase of <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20250731__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zCQ2LmI9F1S2" title="Warrants to purchase stock">210,000 shares of the Company’s common stock at an exercise price of $<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250731__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zHBCfcROuP16" title="Exercisable price per share">1.23 per share. The warrants vested upon grant. The warrants were issued to the underwriters as they acted as placement agents for the SPA noted above. <span id="xdx_90B_ecustom--ClassOfWarrantOrRightsDateFromWhichWarrantsOrRightsExercisableDescription_c20250701__20250731__us-gaap--SubsidiarySaleOfStockAxis__custom--SecurityPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--UnderwritersMember_zSMDVA2C2bj3" title="Warrants exercisable description">The warrants expire five years from the date of grant. On September 17, 2024, upon the closing of the IPO, the Company issued stock warrants to the participating underwriters for the purchase of up to 108,500 shares of the Company’s common stock, at an exercise price of $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240917__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zwX0Hdp5TASg" title="Warrants exercise price">4.80 per share, subject to adjustment. The warrants will be exercisable during the period commencing on March 16, 2025, and ending on September 16, 2029, and may be exercised on a cashless basis under certain circumstances. On September 17, 2024, upon the closing of the IPO, the Company issued a stock warrant to the underwriters for the purchase of <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_pid_c20240917__us-gaap--StatementEquityComponentsAxis__custom--WarrantOneMember_zd0Qam5PSXDg" title="Warrants outstanding, outstanding number of options, shares">19,688 shares of common stock at an exercise price of $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240917__us-gaap--StatementEquityComponentsAxis__custom--WarrantOneMember_zzJwVJQ9wIT" title="Warrants outstanding, weighted average exercise price">2.40 per share. The warrant vested upon grant. The warrant was issued to the underwriters as they were the placement agents for the convertible notes payable (see Note 5). The Company valued the warrant using a Black-Scholes pricing model with the following weighted average assumptions: fair value of the Company’s stock price of $2.46 per share, the expected term of <span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240917__20240917__us-gaap--StatementEquityComponentsAxis__custom--WarrantOneMember_z2BqIerC8qba" title="Expected term">2.5 years, volatility of <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20240917__20240917__us-gaap--StatementEquityComponentsAxis__custom--WarrantOneMember_zTwftgy55rk9" title="Volatility">100%, dividend rate of <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_c20240917__20240917__us-gaap--StatementEquityComponentsAxis__custom--WarrantOneMember_zc0T9SADa9Z6" title="Dividend rate">0%, and risk-free interest rate of <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20240917__20240917__us-gaap--StatementEquityComponentsAxis__custom--WarrantOneMember_z6wx5j0gCVr3" title="Risk free interest rate">3.49%. The fair value of the warrant of $29 was recorded to General and Administrative expense during the year ended December 31, 2024. The warrant expires <span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms_dc_c20240917__20240917__us-gaap--StatementEquityComponentsAxis__custom--WarrantOneMember_zmePiqynDIv8" title="Warrant expiration">five years from the date of grant. The intrinsic value for warrant shares outstanding as of December 31, 2025 was $<span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iI_pn3n3_c20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zA0AGCBbwho2" title="Warrant shares outstanding, intrinsic value">4.

120000000

100000000

0.001

20000000

0.001

20821353

13736597

1550000

4.00

6200000

5524000 872000

232500

108500

4.80

675000

792000

92000

884000

368371

750000

312500

0.60

2.40

1250000

500000

200000

150830

0.60

1.33

333000

133000

172000

51610

0.83

206000

34000

514940

1789000

14000

4000

1664

2.40

666

0.40

3000

500000

367647

500000

166541

500000

157000

2500000

0.001

3750000

1.399

3500000

1.40

3058000

0.001

1.40

will be exercisable six months from issuance and will expire five and a half years from the issuance date. 2500000 3510000

2988000

614000

1650000

877395

1478000

<p id="xdx_890_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_zMayEkIqJv9f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The following table summarizes restricted common stock activity during the years ended December 31, 2024 and 2025: SCHEDULE OF RESTRICTED COMMON STOCK ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number of Restricted Shares</td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fair Value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Grant Date Fair Value</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Unvested, December 31, 2023</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zdbuxdolRnFa" style="text-align: right" title="Number of Restricted Shares, Unvested Beginning balance">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pn3n3_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zIk7XdYRglpl" style="text-align: right" title="Fair Value, Unvested, Beginning balance">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zvBGHxahWw19" style="text-align: right" title="Weighted Average Grant Date Fair Value, Beginning balance">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 46%; text-align: justify">Granted</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zquNd1D4s9il" style="width: 14%; text-align: right" title="Number of Restricted shares Granted">240,341</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_980_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedInPeriodFairValue1_pn3n3_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zjQ9ng6cIf43" style="width: 14%; text-align: right" title="Fair Value, Granted">532</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zctgSPDcCird" style="width: 14%; text-align: right" title="Weighted Average Grant Date Fair Value, Granted">2.21</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Vested</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_iN_pid_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z5gZ9TIqMJQc" style="text-align: right" title="Number of Restricted shares Vested">(68,341</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_iN_pn3n3_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z5DocBDnpWz2" style="text-align: right" title="Fair Value, Vested">(218</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z8NRqRvtHbEg" style="text-align: right" title="Weighted Average Grant Date Fair Value, Vested">3.19</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; text-align: justify">Forfeited</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zIG5mzo53Z84" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Restricted shares Forfeited">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedInPeriodFairValue1_pn3n3_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zc3KdkrQr389" style="border-bottom: Black 1pt solid; text-align: right" title="Fair Value, Forfeited">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zxSVTdAG8dlh" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Grant Date Fair Value, Forfeited">—</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Unvested, December 31, 2024</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zuDhSHkgud4l" style="text-align: right" title="Number of Restricted Shares, Unvested Beginning balance">172,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z3J71Dg7ONp3" style="text-align: right" title="Fair Value, Unvested, Beginning balance">314</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zotk75VMSrX2" style="text-align: right" title="Weighted Average Grant Date Fair Value, Beginning balance">1.83</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zFFYjZl4nvbe" style="text-align: right" title="Number of Restricted shares Granted">745,312</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedInPeriodFairValue1_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zaaqnB6k0jmd" style="text-align: right" title="Fair Value, Granted">981</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zpD2vzFd0ZFa" style="text-align: right" title="Weighted Average Grant Date Fair Value, Granted">1.32</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Vested</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_iN_pid_di_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zNIEiC241yI" style="text-align: right" title="Number of Restricted shares Vested">(144,707</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_iN_pn3n3_di_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zNuzOWfYkA5a" style="text-align: right" title="Fair Value, Vested">(482</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zHNK7xWX3Ze5" style="text-align: right" title="Weighted Average Grant Date Fair Value, Vested">3.33</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; text-align: justify">Forfeited</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zCBz0FuVUiG8" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Restricted shares Forfeited">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedInPeriodFairValue1_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zLqtYEdOMD6a" style="border-bottom: Black 1pt solid; text-align: right" title="Fair Value, Forfeited">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zBkvNNmmcWK6" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Grant Date Fair Value, Forfeited">—</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; text-align: justify">Unvested, December 31, 2025</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zGBLwXoNm9Qc" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Restricted Shares, Unvested Ending balance">772,605</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zcfiYA0O34jk" style="border-bottom: Black 1pt solid; text-align: right" title="Fair Value, Unvested, Ending balance">813</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zNSTOXJZ42Mi" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Grant Date Fair Value, Ending balance">1.05</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table>

240341

532000

2.21

68341

218000

3.19

172000

314000

1.83

745312

981000

1.32

144707

482000

3.33

772605

813000

1.05

667940

875000

57252

75000

50000

100000

50000

92000

226000

78000

14000

30000

43000

20120

31000

16707 33413 482000 813000

The table below summarizes the Company’s warrant activities for years ended December 31, 2024 and 2025: SCHEDULE OF WARRANT ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number of Warrant Shares</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Exercise Price Range Per Share</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%; text-align: justify">Balance, December 31, 2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z0DqfreooQb1" style="width: 14%; text-align: right" title="Warrants Shares, Beginning Balance">150,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><span id="xdx_909_ecustom--ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfOutstandingWarrants_iS_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zsL54D8Bvr3i" title="Exercise Price Range Per Share, Beginning">4.17</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zGd08164eOD2" style="width: 14%; text-align: right" title="Weighted Average Exercise Price Warrant Warrant, Beginning Balance">4.17</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zUxb22iM2l37" style="text-align: right" title="Warrants Shares, Granted">128,188</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_902_ecustom--ShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeGranted_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zwYL8BdhZW0i" title="Exercise Price Range Per Share, Granted">2.40 – <span id="xdx_90B_ecustom--ShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeGranted_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zARetgLlVnB1" title="Exercise Price Range Per Share, Granted">4.80 </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zr9kYpcRvjoh" style="text-align: right" title="Weighted Average Exercise Price Warrant, Granted">4.43</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Cancelled</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zIIq02CDmxX1" style="text-align: right" title="Warrants Shares, Cancelled">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_ecustom--ShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeCancelled_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zR4xOpCE9nub" style="text-align: right" title="Exercise Price Range Per Share, Cancelled">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledWeightedAverageGrantDateFairValue_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zOmOWgQ0yCb3" style="text-align: right" title="Weighted Average Exercise Price Warrant, Cancelled">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_iN_pid_di_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zI2JaOm1N6K4" style="text-align: right" title="Warrants Shares, Exercised">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_909_ecustom--ShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeExercised_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zvz9oBXRdUw3" title="Exercise Price Range Per Share, Exercised">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zsoIoRyS3zE2" style="text-align: right" title="Weighted Average Exercise Price Warrant, Exercised">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; text-align: justify">Forfeited/Expired</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zxq7PUwd532e" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants Shares, Forfeited/Expired">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_ecustom--ShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeForfeited_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z4y9tQE2kbGf" style="border-bottom: Black 1pt solid; text-align: right" title="Exercise Price Range Per Share, Forfeited/Expired">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zykypXb10V7c" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Warrant, Forfeited/Expired">—</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Balance, December 31, 2024</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z609btH9mtsl" style="text-align: right" title="Warrants Shares, Beginning Balance">278,188</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_ecustom--ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfOutstandingWarrants_iS_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_z6N6WJ21jJ61" title="Exercise Price Range Per Share, Beginning">2.40 - <span id="xdx_907_ecustom--ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfOutstandingWarrants_iS_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zG5EqQzVenq7" title="Exercise Price Range Per Share, Beginning">4.80</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z32TMMMegF5k" style="text-align: right" title="Weighted Average Exercise Price Warrant Warrant, Beginning Balance">4.29</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zTZhXbf4Ed0i" style="text-align: right" title="Warrants Shares, Granted">6,670,700</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_ecustom--ShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeGranted_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zXhPOxB3pz45" title="Exercise Price Range Per Share, Granted">0.001 – <span id="xdx_90D_ecustom--ShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeGranted_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zdAW0ynhcsP2" title="Exercise Price Range Per Share, Granted">1.40</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zCeHIw2z793l" style="text-align: right" title="Weighted Average Exercise Price Warrant, Granted">0.87</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Cancelled</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zWM6XhJ7OMF" style="text-align: right" title="Warrants Shares, Cancelled">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--ShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeCancelled_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zRyTk4amyyHk" style="text-align: right" title="Exercise Price Range Per Share, Cancelled">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledWeightedAverageGrantDateFairValue_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_znGGu0gUEaXa" style="text-align: right" title="Weighted Average Exercise Price Warrant, Cancelled">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_iN_pid_di_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zNSBY6GaMROf" style="text-align: right" title="Warrants Shares, Exercised">(2,517,850</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_ecustom--ShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeExercised_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zfczOJZ14VZ1" title="Exercise Price Range Per Share, Exercised">0.001 – <span id="xdx_90D_ecustom--ShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeExercised_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_z5xgcuAL2Rrl" title="Exercise Price Range Per Share, Exercised">0.46</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zWpB3QROoGG3" style="text-align: right" title="Weighted Average Exercise Price Warrant, Exercised">0.004</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; text-align: justify">Forfeited/Expired</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zpTfRb2RuaNj" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants Shares, Forfeited/Expired">(150,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98E_ecustom--ShareBasedCompensationSharesAuthorizedUnderOtherThanStockOptionPlansExercisePriceRangeForfeited_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zw3DWutzwhAk" style="border-bottom: Black 1pt solid; text-align: right" title="Exercise Price Range Per Share, Forfeited/Expired">4.17</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zGSrX6pUcMqi" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Warrant, Forfeited/Expired">4.17</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; text-align: justify">Balance, December 31, 2025</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zbXlgNEU8Iza" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants Shares, Ending Balance">4,281,038</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90B_ecustom--ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfOutstandingWarrants_iE_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zWPM6AVFmnI6" title="Exercise Price Range Per Share, Ending">0.40 – <span id="xdx_90D_ecustom--ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfOutstandingWarrants_iE_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zVchvum777U6" title="Exercise Price Range Per Share, Ending">4.80</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zZcdcnGcjwQa" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Warrant, Ending Balance">1.48</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; text-align: justify">Vested and exercisable, December 31, 2025</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedAndExcercisableInPeriod_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zaVf8hAsVbR4" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Shares Warrants, Vested and exercisable">4,281,038</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_904_ecustom--ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfVestedAndExercisable_iE_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zX0w6vleEBbj" title="Exercise Price Range Per Share, Vested and exercisable">0.40 – <span id="xdx_906_ecustom--ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfVestedAndExercisable_iE_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zdcU4KDryve3" title="Exercise Price Range Per Share, Vested and exercisable">4.80</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ztXj27qgOX5c" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Vested and exercisable">1.48</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table>

150000

4.17

128188

2.40 4.80

4.43

278188

2.40 4.80

4.29

6670700

0.001 1.40

0.87

2517850 0.001 0.46 0.004

-150000

4.17

4281038

0.40 4.80

1.48

4281038 0.40 4.80

1.48

The following table summarizes information concerning outstanding and exercisable warrants as of December 31, 2025: SCHEDULE OF OUTSTANDING AND EXERCISABLE WARRANTS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td colspan="2" style="text-align: right"> </td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants Outstanding</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants Exercisable</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Range of Exercise Prices</td><td style="text-align: center; padding-bottom: 1pt"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number Outstanding</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Average Remaining Contractual Life (in years)</td><td style="text-align: center; padding-bottom: 1pt"> </td><td style="text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Exercise Price</td><td style="text-align: center; padding-bottom: 1pt"> </td><td style="text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number Exercisable</td><td style="text-align: center; padding-bottom: 1pt"> </td><td style="text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Average Remaining Contractual Life (in years)</td><td style="text-align: center; padding-bottom: 1pt"> </td><td style="text-align: center; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Exercise Price</td><td style="text-align: center; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><span id="xdx_90E_ecustom--ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfOutstandingWarrants_iI_pid_c20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantOneMember__srt--RangeAxis__srt--MinimumMember_zo4LIBEEs2z1" title="Range of exercise prices">0.40 - <span id="xdx_908_ecustom--ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfOutstandingWarrants_iI_pid_c20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantOneMember__srt--RangeAxis__srt--MaximumMember_zK9FnQ5vsDWe" title="Range of exercise prices">0.46</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantOneMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zso0q2CIVr4k" title="Warrants Outstanding, Number Outstanding">17,850</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantOneMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zyjiHVTSRY3l" title="Warrants Outstanding, Average Remaining Contractual Life (in years)">4.42</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantOneMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_znhUpyXVIb4" title="Warrants Outstanding, Weighted Average Exercise Price">0.46</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right"><span id="xdx_902_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExercisableNumber_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantOneMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zaQQgMosWdDg" title="Warrants Exercisable, Number Exercisable">17,850</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right"><span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms_dtY_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantOneMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zLdgiZaDZtl7" title="Warrants Exercisable, Average Remaining Contractual Life (in years)">4.42</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><span id="xdx_90A_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePrice_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantOneMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_znORXNtna755" title="Warrants Exercisable, Weighted Average Exercise Price">0.46</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_ecustom--ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfOutstandingWarrants_iI_pid_c20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantTwoMember__srt--RangeAxis__srt--MinimumMember_zpnGDZXewoHd" title="Range of exercise prices">1.23 - <span id="xdx_902_ecustom--ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfOutstandingWarrants_iI_pid_c20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantTwoMember__srt--RangeAxis__srt--MaximumMember_zKCLVu3Xp7u5" title="Range of exercise prices">2.40</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantTwoMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zJdDq72rWe65" title="Warrants Outstanding, Number Outstanding">4,154,688</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantTwoMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zoYBbcQguLg3" title="Warrants Outstanding, Average Remaining Contractual Life (in years)">4.02</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantTwoMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_z1S3Vfmn6Ocb" title="Warrants Outstanding, Weighted Average Exercise Price">1.40</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExercisableNumber_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantTwoMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zpXz6anLNbhf" title="Warrants Exercisable, Number Exercisable">4,154,688</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms_dtY_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantTwoMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zWMg2UJQ7HIl" title="Warrants Exercisable, Average Remaining Contractual Life (in years)">4.02</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90D_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePrice_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantTwoMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zYvf0arxqwDb" title="Warrants Exercisable, Weighted Average Exercise Price">1.40</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_909_ecustom--ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfOutstandingWarrants_iI_pid_c20251231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantThreeMember_zl9lEXYNkfLc" title="Range of exercise prices">4.80</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantThreeMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_zf5LqrQC21W1" title="Warrants Outstanding, Number Outstanding">108,500</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantThreeMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_z6plfu5Ir819" title="Warrants Outstanding, Average Remaining Contractual Life (in years)">3.75</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantThreeMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_zF0Bkv5Qr5vf" title="Warrants Outstanding, Weighted Average Exercise Price">4.80</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_900_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExercisableNumber_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantThreeMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_zTyX2DWA7CJj" title="Warrants Exercisable, Number Exercisable">108,500</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms_dtY_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantThreeMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_zRZdISELzto9" title="Warrants Exercisable, Average Remaining Contractual Life (in years)">3.75</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90A_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePrice_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--WarrantThreeMember__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_zDkHm5TKlsu2" title="Warrants Exercisable, Weighted Average Exercise Price">4.80</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_ecustom--ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfOutstandingWarrants_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zYFYzjuvWeWf" title="Range of exercise prices">0.40 - <span id="xdx_90F_ecustom--ShareBasedCompensationSharesAuthorizedUnderWarrantsExercisePriceRangeNumberOfOutstandingWarrants_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zr6mT1uL7aid" title="Range of exercise prices">4.80</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z1HmJNNK4b5" title="Warrants Outstanding, Number Outstanding">4,281,038</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zrWLZu9Ioeuc" title="Warrants Outstanding, Average Remaining Contractual Life (in years)">4.01</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zFlYa7kgHnlg" title="Warrants Outstanding, Weighted Average Exercise Price">1.48</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExercisableNumber_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z7i4etFKGDgh" title="Warrants Exercisable, Number Exercisable">4,281,038</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms_dtY_c20250101__20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z7yUcCzxslQ8" title="Warrants Exercisable, Average Remaining Contractual Life (in years)">4.01</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePrice_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zHMCWjTyAy8c" title="Warrants Exercisable, Weighted Average Exercise Price">1.48</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 0.40 0.46

17850

P4Y5M1D

0.46

17850 P4Y5M1D 0.46 1.23 2.40

4154688

P4Y7D

1.40

4154688 P4Y7D 1.40 4.80

108500

P3Y9M

4.80

108500 P3Y9M 4.80 0.40 4.80

4281038

P4Y3D

1.48

4281038 P4Y3D 1.48

2500000

0.001

2500000

3750000

1.40

The warrant will be exercisable six months from the date of issuance (July 2025) and will expire five years from the issuance date.

175000

1.40

The warrant expires five years from the date of grant.

35700

0.40

0.46

The warrants expire five years from the date of grant. The warrants expire five years from the date of grant. 17850

17850

11402

210000

1.23

The warrants expire five years from the date of grant.

108500

4.80

19688

2.40

2.46

P2Y6M

0.0349

29000

P5Y

4000

NOTE 6 – COMMITMENTS AND CONTINGENCIES Kairos Exclusive License Agreements with Cedars-Sinai Medical Center (Cedars) The Company has entered into four Exclusive License Agreements with Cedars, each of which grants the Company licensing rights with respect to certain patent rights owned by Cedars as follows: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">1.</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Methods of use of compounds that bind to RelA of NFkB;</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">2.</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Composition and methods for treating fibrosis;</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">3.</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Compositions and methods for treating cancer and autoimmune diseases; and</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">4.</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Method of generating activated T cells for cancer therapy.</td></tr> </table> For each of the exclusive license agreement in items 1, 2 and 3, the Company was required to pay an initial license fee of $5, reimburse Cedars for patent protection costs ranging from approximately $<span id="xdx_901_ecustom--PatentProtectionCosts_pn3n3_c20250101__20251231__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember__srt--RangeAxis__srt--MinimumMember_zTwFLy5xnqJh" title="Patent protection costs">9 to $<span id="xdx_90B_ecustom--PatentProtectionCosts_pn3n3_c20250101__20251231__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember__srt--RangeAxis__srt--MaximumMember_ziGRYz03fpPg" title="Patent protection costs">61, pay an annual maintenance fee of $10, and pay royalties based on 3.75% of net sales and pay other non-royalty sublicense fees ranging from <span id="xdx_901_ecustom--OtherNonroyaltySublicenseFeesPercentage_pid_dp_uPure_c20250101__20251231__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember__srt--RangeAxis__srt--MinimumMember_zFDwTyzIWBTc" title="Other non-royalty sublicense fees percentage">5% to <span id="xdx_904_ecustom--OtherNonroyaltySublicenseFeesPercentage_pid_dp_uPure_c20250101__20251231__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember__srt--RangeAxis__srt--MaximumMember_z33Mu6rPpGih" title="Other non-royalty sublicense fees percentage">35% of sales of products. In addition, for items 1, 2 and 3, the Company is required to pay Cedars based on the following milestones: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">$150 upon the successful completing of Phase I clinical trial;</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">$<span id="xdx_909_ecustom--PaymentForMilestones_pn3n3_c20250101__20251231__srt--ProductOrServiceAxis__custom--ItemOneAndTwoMember__us-gaap--AwardTypeAxis__custom--PhaseTwoMember_zzkEWcgeyH42" title="Payment for milestone">250 (for items 1 and 2) and $<span id="xdx_90B_ecustom--PaymentForMilestones_pn3n3_c20250101__20251231__srt--ProductOrServiceAxis__custom--ItemThreeMember__us-gaap--AwardTypeAxis__custom--PhaseTwoClinicalTrialMember_zEaxuxSToPpj" title="Payment for milestone">500 (for item 3) upon the successful completing of Phase II clinical trial for a product and receipt of Food and Drug Administration (“FDA”) approval for a Phase III clinical trial;</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">$<span id="xdx_901_ecustom--PaymentForMilestones_pn3n3_c20250101__20251231__srt--StatementGeographicalAxis__us-gaap--NonUsMember__dei--LegalEntityAxis__custom--FoodAndDrugAdministrationMember_z82xX5JfEyw1" title="Payment for milestone">1,500 upon receipt of FDA approval of a new drug application or equivalent foreign regulatory approval in a non-United States major commercial market; and</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">$250 upon cumulative net sales exceeding $5,000.</td></tr> </table> For the exclusive license agreement in item 4, the Company is required to pay an initial license fee of $<span id="xdx_908_ecustom--LicenseFee_pn3n3_c20250101__20251231__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember__srt--ProductOrServiceAxis__custom--ItemFourMember_zPqDZv4peQQc" title="License fee">50 upon raising $<span id="xdx_90A_ecustom--MinimumRequirermentOfCapital_iI_pn3n3_c20251231__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember__srt--ProductOrServiceAxis__custom--ItemFourMember_zoqclnQJ3nEh" title="Minimum requirerment of capital">500 in capital, pay an annual maintenance fee of $<span id="xdx_901_eus-gaap--CostMaintenance_pn3n3_c20250101__20251231__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember__srt--ProductOrServiceAxis__custom--ItemFourMember_zSv5rlBxAyyj" title="Annual maintenance fee">10, pay royalties based on <span id="xdx_905_ecustom--RoyaltyPercentage_pid_dp_uPure_c20250101__20251231__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember__srt--ProductOrServiceAxis__custom--ItemFourMember_zMmC1jOQMoVk" title="Royalty percentage">4.25% of patent product sales and <span id="xdx_900_ecustom--PatentProductSalesPercentage_pid_dp_c20250101__20251231__srt--ProductOrServiceAxis__custom--ItemFourMember__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember_zxBOHG6zqT0f" title="Patent product sales">0.5% of other sales and pay other non-royalty sublicense fees ranging from <span id="xdx_900_ecustom--OtherNonroyaltySublicenseFeesPercentage_pid_dp_uPure_c20250101__20251231__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember__srt--RangeAxis__srt--MinimumMember__srt--ProductOrServiceAxis__custom--ItemFourMember_zrRWNoNfWrk1" title="Other non-royalty sublicense fees percentage">5% to <span id="xdx_903_ecustom--OtherNonroyaltySublicenseFeesPercentage_pid_dp_uPure_c20250101__20251231__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember__srt--RangeAxis__srt--MaximumMember__srt--ProductOrServiceAxis__custom--ItemFourMember_z8IJAFicCwm2" title="Other non-royalty sublicense fees percentage">35%. In addition, the Company is required to pay Cedars based on the following milestones: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">$<span id="xdx_905_ecustom--PaymentForMilestones_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--PhaseOneClinicalTrialMember__srt--ProductOrServiceAxis__custom--ItemFourMember_zacuF7ZgDrc8" title="Payment for milestone">150 upon the successful completing of Phase I clinical trial;</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">$<span id="xdx_900_ecustom--PaymentForMilestones_pn3n3_c20250101__20251231__us-gaap--AwardTypeAxis__custom--PhaseTwoClinicalTrialMember__srt--ProductOrServiceAxis__custom--ItemFourMember_zCGfJhi8iqsa" title="Payment for milestone">250 upon the successful completing of Phase II clinical trial and receipt of Food and Drug Administration (“FDA”) or equivalent regulatory agency in another jurisdiction approval for a Phase III clinical trial;</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">$<span id="xdx_90C_ecustom--PaymentForMilestones_pn3n3_c20250101__20251231__srt--ProductOrServiceAxis__custom--ItemFourMember__dei--LegalEntityAxis__custom--FoodAndDrugAdministrationMember_zer8THIXoPWf" title="Payment for milestone">1,500 upon receipt of FDA approval of a new drug application; and</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">$2,500 upon cumulative net sales exceeding $50,000.</td></tr> </table> As of December 31, 2025, no amounts were due under the Exclusive License Agreements between Cedars and the Company. Enviro Therapeutics On June 2, 2021, the Company’s then-wholly owned subsidiary, Enviro, entered into two Exclusive License Agreements with Cedars, which granted Enviro exclusive licensing rights (which include the right to sublicense) with respect to certain patent rights owned by Cedars, as follows: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">an Exclusive License Agreement (the “Enviro-Cedars License Agreement (Mitochondrial DNA)”) for Enviro to develop, manufacture, use and sell products utilized or derived from patent rights worldwide related to the “Compositions and Methods for Treating Diseases and Conditions by Depletion of Mitochondrial DNA from Circulation and for Detection of Mitochondrial DNA” invented by Dr. Neil Bhowmick and others; and</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">an Exclusive License Agreement (the “Enviro-Cedars License Agreement (Endoglin Antagonism)” and, collectively with the Enviro-Cedars License Agreement (Mitochondrial DNA), the “Enviro-Cedars License Agreements”) for Enviro to develop, manufacture, use and sell products utilized or derived from the patent rights and technical information worldwide related to the “Sensitization of Tumors to Therapies Through Endoglin Antagonism” invented by Dr. Neil Bhowmick and others.</td></tr> </table> In exchange for each of the licenses, pursuant to the terms of the Exclusive License Agreements, Enviro was required to pay an upfront license fee in the mid four-figures and low-five figures, respectively. Enviro was also required to reimburse Cedars for the costs in the mid-to-high six figures incurred in the prosecution of the patent rights subject to the Enviro-Cedars License Agreements prior to the date of execution of such agreements, and certain costs and fees then outstanding aggregating in the low-six figures owed by Kairos pursuant to the Kairos-Cedars License Agreements. Pursuant to the Enviro-Cedars License Agreements, Cedars was also to receive royalty payments of a mid-single-digit percentage of net sales of products associated with the licensed patent right and less than one percent of net sales of other products derived from Cedars’ technical information, with a minimum annual royalty fee in the low five-digits due beginning on the third anniversary of the effective date of the Enviro-Cedars License Agreements. To the extent Enviro derived non-royalty sublicensing revenues, a high single-digit to low double-digit percentage of such revenues would be due and payable to Cedars, with the actual percentage of such revenues dependent on the stage of FDA authorization at the time the sublicense revenue is generated. Enviro was also required to pay Cedars in connection with achieving the following Payment Milestones relating to products derived from the patent rights: successful completion of a Phase I clinical trial; successful completion of a Phase II clinical trial, receipt of FDA approval, and approval for a Phase III clinical trial; FDA approval of an NDA or BLA; cumulative net sales exceeding $<span id="xdx_907_eus-gaap--Revenues_pn3n3_c20250101__20251231__srt--ProductOrServiceAxis__custom--PhaseThreeClinicalTrialMember__us-gaap--TypeOfArrangementAxis__custom--EnviroCedarsLicenseAgreementsMember_za0xGUoOAuM4" title="Net sales">50,000; and cumulative net sales exceeding $<span id="xdx_905_eus-gaap--Revenues_pn3n3_c20250101__20251231__srt--ProductOrServiceAxis__custom--ItemOneAndTwoMember__us-gaap--AwardTypeAxis__custom--PhaseThreeMember__us-gaap--TypeOfArrangementAxis__custom--EnviroCedarsLicenseAgreementsMember_ztusoecoy989" title="Net sales">100,000. If all of these payment milestones are met among both of the Exclusive License Agreements, the required milestone payments would total in the mid-to-high seven-figures. Pursuant to the Exclusive License Agreements, Enviro was obligated to meet the following Commercialization Milestones. Pursuant to the Enviro-Cedars License Agreement (Endoglin Antagonism), Enviro was obligated to (1) obtain an IND for a patent product within 1 year of the effective date of the agreement, (2) commence a Phase II trial within 2 years of the effective date of the agreement, and (3) submit an NDA or BLA to the FDA or equivalent regulatory agency in another jurisdiction within 7 years of the effective date of the agreement. Pursuant to the Enviro-Cedars License Agreement (Mitochondrial DNA), Enviro was obligated to (1) complete preclinical studies of a patent product within 2 years of the effective date of the agreement, (2) complete toxicology studies within 2.5 years of the effective date of the agreement, (3) obtain IND within 3 years of the effective date of the agreement, (4) begin a Phase I trial within 4 years of the effective date of the agreement, and (5) submit an NDA or BLA to the FDA or equivalent regulatory agency in another jurisdiction within 7 years of the effective date of the agreement. If the Commercialization Milestones are not met or extended, Cedars may convert the exclusive licenses into non-exclusive licenses or to a co-exclusive licenses or terminate the licenses. The Exclusive License Agreements will, unless sooner terminated, continue in effect on a country-by-country basis until the last of the patents covering the patent rights or future patent rights expires. Under the terms of the Enviro-Cedars License Agreements, unless waived by Cedars, the agreements would automatically terminate: (a) if Enviro ceases, dissolves or winds up its business operations; (b) if performance by either party jeopardizes the licensure, accreditation or tax exempt status of Cedars or the agreement is deemed illegal by a governmental body; (c) within 30 days for non-payment of royalties or if Enviro fails to undertake commercially reasonable efforts to exploit the patent rights or future patent rights; (d) within 60 days of Cedars’ failure to cure any breach or default of a material obligation under the agreements; (e) within 90 days of Enviro’s failure to cure any breach or default of a material obligation under the agreements; or (f) upon mutual written agreement of the parties. Novation Agreements On October 1, 2025, the Board of Directors approved the entry of Kairos and Enviro into a novation agreement (the “Cedars Novation Agreement”) with Cedars. The Cedars Novation Agreement was entered into on October 1, 2025, but effective as of April 17, 2025, for purposes of transferring the exclusive license of two patents from Enviro, as the original licensee, to Kairos, as the new licensee. As the new licensee of the two patents, Kairos accepted and assumed all obligations and liabilities that may arise under the Exclusive License Agreements from Enviro and Enviro is relieved of all of its liabilities and obligations under the license agreements. In addition, on October 1, 2025, the Board approved the Company’s entry into a novation agreement (the “Tracon Novation Agreement”) with Tracon Pharmaceuticals, Inc. (the “Tracon”) and Enviro pursuant to which Enviro’s rights and obligations under the license and supply agreement between Tracon, Enviro and Kairos, originally dated May 21, 2021, as amended to date (the “Tracon License Agreement”), were transferred from Enviro to Kairos and Enviro was relieved of any further liabilities or obligations under the license and supply agreement. Under the Tracon License Agreement, Tracon had granted Enviro exclusive access to its TRC105 and CD105 technologies, which Kairos has now assumed pursuant to the Tracon Novation Agreement. Agreement with Lonza Sales AG On November 12, 2025, the Company entered into an amendment (the “Lonza Amendment”) to the sales agreement with Lonza Sales AG (“Lonza”), originally dated February 14, 2008, pursuant to which the Company agreed to purchase and Lonza agreed to testing of standards and the preparation to manufacture ENV105 antibody to be used in the Company’s Phase 2 clinical trial. The Company agreed to pay a total of $1,143 in consideration, which will be paid over time as each of the 13 stages of the Lonza Amendment are completed. As of December 31, 2025, Lonza’s testing and preparation of the ENV105 antibody had yet to be completed and the Company had yet to make any payments to Lonza. Legal Matters To the Company’s knowledge, it is not currently the subject of any material legal proceeding. In the future, the Company may be involved in actual and/or threatened legal proceedings, claims, investigations and government inquiries arising in the ordinary course of our business, including legal proceedings, claims, investigations and government inquiries involving intellectual property, data privacy and security, other torts, illegal or objectionable content, consumer protection, securities, employment, contractual rights, civil rights infringement, false or misleading advertising, or other legal claims relating to our business.

5000 9000 61000

10000

0.0375 0.05 0.35 150000 250000 500000 1500000 250000

5000000

50000 500000

10000

0.0425 0.005 0.05 0.35 150000 250000 1500000 2500000

50000000

100000000

(1) obtain an IND for a patent product within 1 year of the effective date of the agreement, (2) commence a Phase II trial within 2 years of the effective date of the agreement, and (3) submit an NDA or BLA to the FDA or equivalent regulatory agency in another jurisdiction within 7 years of the effective date of the agreement. Pursuant to the Enviro-Cedars License Agreement (Mitochondrial DNA), Enviro was obligated to (1) complete preclinical studies of a patent product within 2 years of the effective date of the agreement, (2) complete toxicology studies within 2.5 years of the effective date of the agreement, (3) obtain IND within 3 years of the effective date of the agreement, (4) begin a Phase I trial within 4 years of the effective date of the agreement, and (5) submit an NDA or BLA to the FDA or equivalent regulatory agency in another jurisdiction within 7 years of the effective date of the agreement. If the Commercialization Milestones are not met or extended, Cedars may convert the exclusive licenses into non-exclusive licenses or to a co-exclusive licenses or terminate the licenses.

1143000

NOTE 7 – INCOME TAXES Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. A full valuation allowance is established against all net deferred tax assets as of December 31, 2025 and 2024 based on estimates of recoverability. While the Company has optimistic plans for its business strategy, it determined that such a valuation allowance was necessary given the current and expected near-term losses and the uncertainty with respect to its ability to generate sufficient profits from its business model. Because of the impacts of the valuation allowance, there was no income tax expense or benefit for the years ended December 31, 2025 and 2024. A reconciliation of the differences between the effective and statutory income tax rates for the years ended December 31, 2025 and 2024 are shown below: SCHEDULE OF RECONCILIATION OF THE DIFFERENCES BETWEEN THE EFFECTIVE AND STATUTORY INCOME TAX RATES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20250101__20251231_zJsdsu7ipPB8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Percent</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49B_20240101__20241231_z2N6KT8R6qrl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Percent</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Percent</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Percent</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_40A_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_maITEBzjTX_zIOF3uUze7ej" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left">Federal statutory rates</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(1,144</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_987_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_maETR001_c20250101__20251231_zCqXUHnrBNH9" style="width: 11%; text-align: right" title="Federal statutory rates, percentage">21.0</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(547</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_981_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_maETR001_c20240101__20241231_zSU8KiZSfja5" style="width: 11%; text-align: right" title="Federal statutory rates, percentage">21.0</td><td style="width: 1%; text-align: left">%</td></tr> <tr id="xdx_402_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_maITEBzjTX_z9Ep20l2Lt1c" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">State income taxes</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(381</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_maETR001_c20250101__20251231_zrUQtrssreJ7" style="text-align: right" title="State income taxes, percentage">7.0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(182</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_maETR001_c20240101__20241231_z3aVZKsJeNv4" style="text-align: right" title="State income taxes, percentage">7.0</td><td style="text-align: left">%</td></tr> <tr id="xdx_401_eus-gaap--IncomeTaxReconciliationOtherAdjustments_maITEBzjTX_z1a1D57uf8M" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Other</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"></td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_pid_dp_uPure_maETR001_c20250101__20251231_zrq886co2iYi" style="text-align: right" title="Other, percentage">-</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(13</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_pid_dp_uPure_maETR001_c20240101__20241231_zRqR7cZUt7Hg" style="text-align: right" title="Other, percentage">0.5</td><td style="text-align: left">%</td></tr> <tr id="xdx_40E_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maITEBzjTX_z82nakRxMCQl" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Valuation allowance against net deferred tax assets</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,525</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_maETR001_c20250101__20251231_zKOWVkayYQR1" style="border-bottom: Black 1pt solid; text-align: right" title="Valuation allowance against net deferred tax assets, percentage">(28.0</td><td style="padding-bottom: 1pt; text-align: left">)%</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">742</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_maETR001_c20240101__20241231_zMXIK97LsBT2" style="border-bottom: Black 1pt solid; text-align: right" title="Valuation allowance against net deferred tax assets, percentage">(28.5</td><td style="padding-bottom: 1pt; text-align: left">)%</td></tr> <tr id="xdx_408_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBzjTX_zyPj6GpMeBQ8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Effective rate</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_mtETR001_c20250101__20251231_zOXqrnmPiXkc" style="border-bottom: Black 2.5pt double; text-align: right" title="Effective rate, percentage">-</td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_c20240101__20241231_z1c51D7QMLr2" style="border-bottom: Black 2.5pt double; text-align: right" title="Effective rate, percentage">-</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr> </table> At December 31, 2024 and 2023, the significant components of the deferred tax assets are summarized below: SCHEDULE OF SIGNIFICANT COMPONENTS OF THE DEFERRED TAX ASSETS AND LIABILITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49F_20251231_z2a8pmh0NwK3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20241231_zvYDMjaUiYo2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-decoration: underline; text-align: left">Deferred income tax assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_i01I_pn3n3_maDTATDzYaQ_zfi09sfSPTy9" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 56%; text-align: left">Net operating loss carryforwards</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">2,766</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">1,199</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_i01I_pn3n3_maDTATDzYaQ_zEqjkqWUGlP6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Capitalized R&D expenses</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">482</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">90</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsTaxDeferredExpense_i01TI_pn3n3_mtDTATDzYaQ_maDTAGzTTB_zDrY1VuZ0cxe" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; text-align: left">Total deferred income tax assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,248</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,289</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsValuationAllowance_i01NI_pn3n3_di_msDTAGzTTB_zM1ORMUXvye8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Less: valuation allowance</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(3,009</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(841</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsGross_i01TI_pn3n3_mtDTAGzTTB_maDTALNz2NS_zlPXicNDnmil" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Total net deferred income taxes</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">239</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">448</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-decoration: underline; text-align: left">Deferred income tax liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_400_ecustom--DeferredTaxLiabilitiesAmortizationOfIntangibles_i01NI_pn3n3_di_maDITLzKso_zuUUrtrsQ77g" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Amortization of intangibles</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(17</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(62</td><td style="text-align: left">)</td></tr> <tr id="xdx_40C_ecustom--DeferredTaxLiabilitiesAccrualToCash_i01NI_pn3n3_di_maDITLzKso_zycLQrHCWX63" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Accrual to cash</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(222</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(386</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_400_eus-gaap--DeferredIncomeTaxLiabilities_i01NTI_pn3n3_di_msDTALNz2NS_mtDITLzKso_zEcFz8imJYU4" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Total deferred income tax liabilities</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(239</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(448</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_mtDTALNz2NS_zWJ01gI12a51" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total deferred income tax assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> As of December 31, 2025, the Company has net operating loss (“NOL”) carryforwards of approximately $9,900 and are subject to IRS code section 382 limitations. Of the total federal net operating loss, approximately $9,600 has an indefinite carryforward period as of December 31, 2025. The remaining federal and California net operating loss carryforwards will expire through December 31, 2045, unless previously utilized. NOL carryforwards may be subject to limitation under Sections 382 of the Internal Revenue Code, and similar state provisions which limit the amount carryforwards that can be utilized to offset future taxable income. In general, an ownership change, as defined by Sections 382, results from transactions increasing ownership of certain stockholders in the stock of the corporation by more than 50 percentage points over a three-year period. The Company does not anticipate performing a complete analysis of the limitation on the annual use of the net operating loss carryforwards until the time that it anticipates it will be able to utilize these tax attributes. This could impose an annual limit or reduction on the Company’s ability to utilize net operating loss carryforwards and could cause U.S. federal income taxes to be paid earlier than otherwise would be paid if such limitations were not in effect. The U.S. federal net operating loss carryforwards are stated before any such anticipated limitations. If a change in ownership were to have occurred, the Company’s NOL carryforwards could be eliminated or restricted.

A reconciliation of the differences between the effective and statutory income tax rates for the years ended December 31, 2025 and 2024 are shown below: SCHEDULE OF RECONCILIATION OF THE DIFFERENCES BETWEEN THE EFFECTIVE AND STATUTORY INCOME TAX RATES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20250101__20251231_zJsdsu7ipPB8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Percent</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49B_20240101__20241231_z2N6KT8R6qrl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Percent</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Percent</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Percent</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_40A_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_maITEBzjTX_zIOF3uUze7ej" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left">Federal statutory rates</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(1,144</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_987_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_maETR001_c20250101__20251231_zCqXUHnrBNH9" style="width: 11%; text-align: right" title="Federal statutory rates, percentage">21.0</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(547</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_981_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_maETR001_c20240101__20241231_zSU8KiZSfja5" style="width: 11%; text-align: right" title="Federal statutory rates, percentage">21.0</td><td style="width: 1%; text-align: left">%</td></tr> <tr id="xdx_402_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_maITEBzjTX_z9Ep20l2Lt1c" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">State income taxes</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(381</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_maETR001_c20250101__20251231_zrUQtrssreJ7" style="text-align: right" title="State income taxes, percentage">7.0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(182</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_maETR001_c20240101__20241231_z3aVZKsJeNv4" style="text-align: right" title="State income taxes, percentage">7.0</td><td style="text-align: left">%</td></tr> <tr id="xdx_401_eus-gaap--IncomeTaxReconciliationOtherAdjustments_maITEBzjTX_z1a1D57uf8M" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Other</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"></td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_pid_dp_uPure_maETR001_c20250101__20251231_zrq886co2iYi" style="text-align: right" title="Other, percentage">-</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(13</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_pid_dp_uPure_maETR001_c20240101__20241231_zRqR7cZUt7Hg" style="text-align: right" title="Other, percentage">0.5</td><td style="text-align: left">%</td></tr> <tr id="xdx_40E_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maITEBzjTX_z82nakRxMCQl" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Valuation allowance against net deferred tax assets</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,525</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_maETR001_c20250101__20251231_zKOWVkayYQR1" style="border-bottom: Black 1pt solid; text-align: right" title="Valuation allowance against net deferred tax assets, percentage">(28.0</td><td style="padding-bottom: 1pt; text-align: left">)%</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">742</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_maETR001_c20240101__20241231_zMXIK97LsBT2" style="border-bottom: Black 1pt solid; text-align: right" title="Valuation allowance against net deferred tax assets, percentage">(28.5</td><td style="padding-bottom: 1pt; text-align: left">)%</td></tr> <tr id="xdx_408_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBzjTX_zyPj6GpMeBQ8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Effective rate</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_mtETR001_c20250101__20251231_zOXqrnmPiXkc" style="border-bottom: Black 2.5pt double; text-align: right" title="Effective rate, percentage">-</td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_c20240101__20241231_z1c51D7QMLr2" style="border-bottom: Black 2.5pt double; text-align: right" title="Effective rate, percentage">-</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr> </table>

-1144000

0.210

-547000

0.210

-381000

0.070

-182000

0.070

-13000

0.005

1525000

-0.280

742000

-0.285

At December 31, 2024 and 2023, the significant components of the deferred tax assets are summarized below: SCHEDULE OF SIGNIFICANT COMPONENTS OF THE DEFERRED TAX ASSETS AND LIABILITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49F_20251231_z2a8pmh0NwK3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20241231_zvYDMjaUiYo2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-decoration: underline; text-align: left">Deferred income tax assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_i01I_pn3n3_maDTATDzYaQ_zfi09sfSPTy9" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 56%; text-align: left">Net operating loss carryforwards</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">2,766</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">1,199</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_i01I_pn3n3_maDTATDzYaQ_zEqjkqWUGlP6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Capitalized R&D expenses</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">482</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">90</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsTaxDeferredExpense_i01TI_pn3n3_mtDTATDzYaQ_maDTAGzTTB_zDrY1VuZ0cxe" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; text-align: left">Total deferred income tax assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,248</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,289</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsValuationAllowance_i01NI_pn3n3_di_msDTAGzTTB_zM1ORMUXvye8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Less: valuation allowance</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(3,009</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(841</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsGross_i01TI_pn3n3_mtDTAGzTTB_maDTALNz2NS_zlPXicNDnmil" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Total net deferred income taxes</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">239</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">448</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-decoration: underline; text-align: left">Deferred income tax liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_400_ecustom--DeferredTaxLiabilitiesAmortizationOfIntangibles_i01NI_pn3n3_di_maDITLzKso_zuUUrtrsQ77g" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Amortization of intangibles</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(17</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(62</td><td style="text-align: left">)</td></tr> <tr id="xdx_40C_ecustom--DeferredTaxLiabilitiesAccrualToCash_i01NI_pn3n3_di_maDITLzKso_zycLQrHCWX63" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Accrual to cash</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(222</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(386</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_400_eus-gaap--DeferredIncomeTaxLiabilities_i01NTI_pn3n3_di_msDTALNz2NS_mtDITLzKso_zEcFz8imJYU4" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Total deferred income tax liabilities</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(239</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(448</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_mtDTALNz2NS_zWJ01gI12a51" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total deferred income tax assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

2766000

1199000

482000

90000

3248000

1289000

3009000

841000

239000

448000

17000 62000 222000 386000

239000

448000

the Company has net operating loss (“NOL”) carryforwards of approximately $9,900 and are subject to IRS code section 382 limitations. Of the total federal net operating loss, approximately $9,600 has an indefinite carryforward period as of December 31, 2025. The remaining federal and California net operating loss carryforwards will expire through December 31, 2045, unless previously utilized. NOL carryforwards may be subject to limitation under Sections 382 of the Internal Revenue Code, and similar state provisions which limit the amount carryforwards that can be utilized to offset future taxable income. In general, an ownership change, as defined by Sections 382, results from transactions increasing ownership of certain stockholders in the stock of the corporation by more than 50 percentage points over a three-year period. The Company does not anticipate performing a complete analysis of the limitation on the annual use of the net operating loss carryforwards until the time that it anticipates it will be able to utilize these tax attributes. This could impose an annual limit or reduction on the Company’s ability to utilize net operating loss carryforwards and could cause U.S. federal income taxes to be paid earlier than otherwise would be paid if such limitations were not in effect. The U.S. federal net operating loss carryforwards are stated before any such anticipated limitations. If a change in ownership were to have occurred, the Company’s NOL carryforwards could be eliminated or restricted.

9900000

NOTE 8 – GAIN ON SETTLEMENT OF ACCOUNTS PAYABLE On October 17, 2024, the Company entered into a Settlement Agreement with the Company’s former outside legal counsel. In connection with the agreement, the law firm agreed to settle the amount the Company owed them, which totaled $749, in exchange for a payment of $150. This resulted in a gain of $<span id="xdx_90C_ecustom--GainOnSettlementOfAccountsPayable_pn3n3_c20241017__20241017__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember_z7qjBofNaEg3" title="Gain on settlement of accounts payable">599 for the Company. In October 2024, the Company made the $150 payment to the law firm. As of December 31, 2024, no amounts were owed to the law firm.

749000

150000 599000 150000

NOTE 9 – SEGMENT INFORMATION The Company operates and manages its business as one reportable segment and operates as a clinical-stage biopharmaceutical company. The Company’s current focus is on developing immunotherapy and cell therapies for the treatment of cancer. The Company’s Chief Operating Decision Maker (“CODM”) is the Chief Executive Officer, who reviews financial information presented and decides how to allocate resources based on net income (loss). Net income (loss) is used for evaluating financial performance. Significant segment expenses include research and development, officer compensation, insurance, and stock-based compensation. Operating expenses include all the remaining costs necessary to operate our business, which primarily include external professional services and other administrative expenses. The following table presents the significant segment expenses and other segment items regularly reviewed by our CODM: SCHEDULE OF SEGMENT EXPENSES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20250101__20251231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zcuykOcOE0f1" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49B_20240101__20241231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zeRadrtmgsDf" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Years ended December 31,</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_40A_eus-gaap--Revenues_pn3n3_zwV0aine9ili" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Revenue</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Less:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_zd5pQMMAIkCk" style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: left">Research and development, less officer compensation</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">1,837</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">414</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--OfficersCompensation_pn3n3_z7GUfqik1r6a" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Officer compensation and wages</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">716</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">119</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--InsuranceRecoveries_pn3n3_zMloMc2jlvyl" style="vertical-align: bottom; background-color: White"> <td>Insurance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">385</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">151</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_zvxsuWMEQYLc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Stock-based compensation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">482</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">218</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--OperatingExpenses_pn3n3_z5e0YNbPSyMf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Operating expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,152</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,441</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--OtherOperatingIncomeExpenseNet_pn3n3_zTOV6ZZtWvJe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Other income (expenses)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">125</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(260</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_403_eus-gaap--NetIncomeLoss_pn3n3_zVmckMYgdZ1l" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">NET LOSS</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(5,447</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(2,603</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table>

SCHEDULE OF SEGMENT EXPENSES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20250101__20251231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zcuykOcOE0f1" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49B_20240101__20241231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zeRadrtmgsDf" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Years ended December 31,</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2024</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_40A_eus-gaap--Revenues_pn3n3_zwV0aine9ili" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Revenue</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Less:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_zd5pQMMAIkCk" style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: left">Research and development, less officer compensation</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">1,837</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">414</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--OfficersCompensation_pn3n3_z7GUfqik1r6a" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Officer compensation and wages</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">716</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">119</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--InsuranceRecoveries_pn3n3_zMloMc2jlvyl" style="vertical-align: bottom; background-color: White"> <td>Insurance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">385</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">151</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_zvxsuWMEQYLc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Stock-based compensation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">482</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">218</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--OperatingExpenses_pn3n3_z5e0YNbPSyMf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Operating expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,152</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,441</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--OtherOperatingIncomeExpenseNet_pn3n3_zTOV6ZZtWvJe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Other income (expenses)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">125</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(260</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_403_eus-gaap--NetIncomeLoss_pn3n3_zVmckMYgdZ1l" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">NET LOSS</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(5,447</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(2,603</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table>

1837000

414000

716000

119000

385000

151000

482000

218000

2152000

1441000

125000

-260000

-5447000

-2603000

NOTE 10 – SUBSEQUENT EVENTS In January 2026, the Company filed a shelf registration statement on Form S-3 (SEC File No. 333-292686) registering up to $<span id="xdx_903_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn6n6_c20260101__20260131__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zBSlXFk8FAyf" title="Number of common stock issued">75 million in aggregate securities and, in conjunction therewith, filed a prospectus supplement for the sale of up to $<span id="xdx_90C_eus-gaap--SaleOfStockConsiderationReceivedPerTransaction_pn5n6_c20260101__20260131__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--ATMAgreementMember_zmtDrvMokjf6" title="Sale of stock value">4.5 million of common stock pursuant to an At the Market Offering Agreement (the “ATM Agreement”) with H.C. Wainwright and Co., LLC (the “Placement Agent”). Under the ATM Agreement, the Placement Agent will be entitled to <span id="xdx_908_eus-gaap--SaleOfStockPercentageOfOwnershipAfterTransaction_pid_dp_uPure_c20260101__20260131__us-gaap--TypeOfArrangementAxis__custom--ATMAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zctqfOuRbVI5" title="Sale of stock rate">3.0% of the gross proceeds of any sales made under the ATM Agreement. As a result of the ATM offering, subsequent to December 31, 2025, the Company raised $<span id="xdx_90D_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pp0p0_c20260101__20260331__us-gaap--TypeOfArrangementAxis__custom--ATMAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zHMdzl9bxoP6" title="Sale of stock">385 through the sale of <span id="xdx_90F_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pn5n6_c20260101__20260331__us-gaap--TypeOfArrangementAxis__custom--ATMAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zE7YrUoRSuj8" title="Sale of stock shares">589,845 shares of its common stock. On March 2, 2026, the Company entered into a binding term sheet with Celyn Therapeutics, Inc., a privately held biotechnology company, regarding a proposed asset acquisition of CL-273, an investigational, reversible, wild type sparing pan EGFR small molecule inhibitor being developed by Eilean Therapeutics for EGFR mutant non-small cell lung cancer. Pursuant to the term sheet, the Company will receive 100% of the development, manufacturing, commercialization rights, patent prosecution and patent filing rights worldwide to CL-273 in exchange for upfront payment of 16.5% of the Company’s outstanding capital stock, with such stock to be issued in the form of Common Stock or convertible preferred stock, and milestone payments of (i) $15 million payable at NDA or BLA FDA, with such payment to be made in combination of cash and stock and (ii) 2% royalties from net revenue generated from sales in the U.S. for the life of the intellectual property. Closing is subject to satisfactory completion of due diligence and negotiation of a definitive acquisition agreement. On March 27, 2026, the Company entered into an additional statement of work to the sales agreement with Lonza Sales AG (“Lonza”), originally dated February 14, 2008, pursuant to which the Company agreed to purchase and Lonza agreed to testing of standards and the preparation to manufacture ENV105 antibody to be used in the Company’s Phase 2 clinical trial. The Company agreed to pay an approximate total of $<span id="xdx_90F_eus-gaap--PaymentsToAcquireProductiveAssets_pn3n3_c20260327__20260327__us-gaap--TypeOfArrangementAxis__custom--LonzaAmendmentMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z5SmsQB8nf7" title="Payments for purchase of assets">2,000 in consideration, which will be paid over time as each of the 13 stages of the Lonza Amendment are completed. See Note 6 for further details.

75000000

4500000

0.030

385

589845000000

15000000

0.02

2000000

December 16, 2025 John S. Yu Chief Executive Officer and Chairman of the Board of Directors true 3500000 December 31, 2026 true Kairos Agreement with Prevail Infoworks, Inc. Kairos Agreement with PreCheck Health Services, Inc. Kairos Agreement with CEO.CA Technologies Ltd. Kairos Agreement with Belair Capital Advisors Inc. Kairos Agreement with Cross Current Capital LLC